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Worldwide trends in blood pressure from 1975 to 2015: 
a pooled analysis of 1479 population-based measurement 
studies with 19·1 million participants
NCD Risk Factor Collaboration (NCD-RisC)*
Summary
Background Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. 
We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and 
number of people with, raised blood pressure, deﬁ ned as systolic blood pressure of 140 mm Hg or higher or diastolic 
blood pressure of 90 mm Hg or higher.
Methods For this analysis, we pooled national, subnational, or community population-based studies that had 
measured blood pressure in adults aged 18 years and older. We used a Bayesian hierarchical model to estimate trends 
from 1975 to 2015 in mean systolic and mean diastolic blood pressure, and the prevalence of raised blood pressure for 
200 countries. We calculated the contributions of changes in prevalence versus population growth and ageing to the 
increase in the number of adults with raised blood pressure.
Findings We pooled 1479 studies that had measured the blood pressures of 19·1 million adults. Global age-standardised 
mean systolic blood pressure in 2015 was 127·0 mm Hg (95% credible interval 125·7–128·3) in men and 122·3 mm Hg 
(121·0–123·6) in women; age-standardised mean diastolic blood pressure was 78·7 mm Hg (77·9–79·5) for men and 
76·7 mm Hg (75·9–77·6) for women. Global age-standardised prevalence of raised blood pressure was 24·1% 
(21·4–27·1) in men and 20·1% (17·8–22·5) in women in 2015. Mean systolic and mean diastolic blood pressure 
decreased substantially from 1975 to 2015 in high-income western and Asia Paciﬁ c countries, moving these countries 
from having some of the highest worldwide blood pressure in 1975 to the lowest in 2015. Mean blood pressure also 
decreased in women in central and eastern Europe, Latin America and the Caribbean, and, more recently, central 
Asia, Middle East, and north Africa, but the estimated trends in these super-regions had larger uncertainty than in 
high-income super-regions. By contrast, mean blood pressure might have increased in east and southeast Asia, 
south Asia, Oceania, and sub-Saharan Africa. In 2015, central and eastern Europe, sub-Saharan Africa, and south Asia 
had the highest blood pressure levels. Prevalence of raised blood pressure decreased in high-income and some 
middle-income countries; it remained unchanged elsewhere. The number of adults with raised blood pressure 
increased from 594 million in 1975 to 1·13 billion in 2015, with the increase largely in low-income and middle-income 
countries. The global increase in the number of adults with raised blood pressure is a net eﬀ ect of increase due to 
population growth and ageing, and decrease due to declining age-speciﬁ c prevalence.
Interpretation During the past four decades, the highest worldwide blood pressure levels have shifted from 
high-income countries to low-income countries in south Asia and sub-Saharan Africa due to opposite trends, while 
blood pressure has been persistently high in central and eastern Europe.
Funding Wellcome Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Raised blood pressure is the leading global risk factor for 
cardiovascular diseases and chronic kidney disease.1 One 
of the global non-communicable disease (NCD) targets 
adopted by the World Health Assembly in 2013 is to lower 
the prevalence of raised blood pressure, deﬁ ned as systolic 
blood pressure of 140 mm Hg or higher or diastolic blood 
pressure of 90 mm Hg or higher, by 25% compared with 
its 2010 level by 2025.2 Consistent global information is 
needed to understand how countries compare on blood 
pressure levels and trends, and where interventions to 
curtail the rise in blood pressure are most needed.
The prevalence of raised blood pressure measures the 
number of high-risk people irrespective of treatment 
status, and is the indicator used in the global NCD target. 
However, blood pressure has a log-linear association with 
cardiovascular diseases and chronic kidney disease that 
continues well below the threshold for raised blood 
pressure, and treatment provides similar proportional risk 
reductions irrespective of pretreatment blood pressure.3,4 
Trends in mean population blood pressure measure how 
blood pressure distribution has shifted over time.
We pooled population-based data to estimate national, 
regional, and global trends from 1975 to 2015 in mean 
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systolic and mean diastolic blood pressure, and in the 
prevalence of raised blood pressure, for adults aged 
18 years and older in 200 countries and territories. We 
also estimated trends in the number of adults with raised 
blood pressure, and calculated how much these trends 
are attributable to changes in prevalence versus changes 
in population size and age structure.
Methods
Study design and data sources
For this pooled analysis, we included data collected from 
samples of a national, subnational (ie, covering one or 
more subnational regions), or community (one or a small 
number of communities) population in which 
participants’ blood pressure had been measured. Our 
methods for identifying and accessing data sources are 
described in the appendix (pp 2–6). When a study 
measured blood pressure more than once in participants 
(1053 [86%] of 1220 studies for which information about 
number of measurements was available), we discarded 
the ﬁ rst measurement, and used the average of the 
remainder.
292 (20%) of the 1479 data sources we analysed 
(2298 [16%] of 14 391 age-sex-study-speciﬁ c data points) 
that were from a previous global pooling5 or extracted 
from publications did not have data on one or more of 
our primary outcomes. We used regressions to convert 
available data in these sources to the missing primary 
outcomes because the various blood pressure outcomes 
are correlated.6 Details of conversion (or so-called 
cross-walking) regressions and their coeﬃ  cients are 
presented in the appendix (pp 7, 8, 44–152).
Statistical analysis
The statistical model used to estimate means and 
prevalence by country, year, and age is described in detail 
in a statistical paper and related substantive papers.5,7,8 In 
summary, we organised countries into 21 regions, mainly 
on the basis of geography and national income, which 
we further aggregated into nine “super-regions” 
(appendix pp 14, 15). The model had a hierarchical 
structure in which estimates for each country and year 
were informed by its own data, if available, and by data 
from other years in the same country and from other 
countries, especially countries in the same region with 
data for similar time periods. The hierarchical structure 
shares information to a greater extent when data are non-
existent or weakly informative (eg, have a small sample 
size or are not national), and to a lesser extent for data-
rich countries and regions.
The model incorporated non-linear time trends and age 
patterns. It allowed the age association of blood pressure 
Research in context
Evidence before this study
We searched MEDLINE (via PubMed) for articles published in 
English, Spanish, Portuguese, Chinese, Italian, French, or 
Farsi between Jan 1, 1950, and Feb 19, 2014, using the search 
terms (“blood pressure”[Mesh:NoExp] OR 
“hypertension”[Mesh:NoExp]) AND (“Humans”[Mesh]). 
We screened articles according to the inclusion and exclusion 
criteria described in the appendix.
Some studies, including the MONICA Project, have reported 
on blood pressure change or trends in one or more countries. 
Two previous global analyses, done more than a decade ago, 
pooled data from diﬀ erent countries and reported mean 
systolic blood pressure or prevalence of hypertension in the 
year 2000 for the world and its major regions. A more recent 
analysis published in 2016 pooled 135 studies to estimate 
global and regional hypertension prevalence in 2000 and 
2010, but did not report changes in mean blood pressure, 
which reﬂ ect shifts in the population distribution of blood 
pressure. None of these studies provided consistent estimates 
for all countries or accounted for the fact that the data used 
were collected in diﬀ erent years. The only analysis of trends at 
the country level reported mean systolic blood pressure from 
1980 to 2008 but did not report mean diastolic blood 
pressure or prevalence of raised blood pressure, which is of 
clinical relevance and needed for monitoring progress towards 
the global target.
Added value of this study
This study provides the most complete picture of trends in 
adult blood pressure for all countries in the world with the 
longest observation period of any global blood pressure study 
to our knowledge, and includes trends in mean diastolic blood 
pressure and prevalence of raised blood pressure, which were 
not included in previous studies and are of clinical, public 
health, and health systems signiﬁ cance. We also estimated 
trends in the number of adults with raised blood pressure, and 
how much these trends are driven by changes in prevalence 
versus population size and age structure.
Implications of all the available evidence
During the past four decades, the highest levels of blood 
pressure worldwide have shifted from high-income countries to 
low-income and middle-income countries in south Asia and 
sub-Saharan Africa, while blood pressure has been persistently 
high in central and eastern Europe. The global target of reducing 
raised blood pressure prevalence by 25% by 2025 is unlikely to be 
achieved in these regions. The number of people with raised 
blood pressure has risen worldwide, with the increase happening 
mainly in low-income and middle-income countries. 
Population-based interventions throughout the life-course and 
pharmacological treatment for people with high absolute risk or 
people with substantially raised blood pressure should be a part 
of any eﬀ ort to address the global burden of non-communicable 
diseases, especially in the poorest countries. 
See Online for appendix
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to vary across populations, and the rise in means and 
prevalence over age to be steeper where blood pressure is 
higher.9,10 The model accounted for the possibility that 
blood pressure in subnational and community studies 
might systematically diﬀ er from nationally representative 
ones, and might also have larger variation than in national 
studies; the model also accounted for rural–urban 
diﬀ erences in blood pressure, and used it to adjust 
rural-only and urban-only studies. The statistical model 
included covariates that help predict blood pressure, 
including mean number of years of education, proportion 
of national population living in urban areas, and a 
summary measure of availability of diﬀ erent food types 
for human consumption (appendix pp 9, 10).
We ﬁ tted the statistical model with the Markov chain 
Monte Carlo algorithm, and obtained 5000 post-burn-in 
samples from the posterior distribution of model 
parameters, which were in turn used to obtain 
the posterior distributions of primary outcomes. The 
reported credible intervals (CrI) represent the 
2·5th to 97·5th percentiles of the posterior distributions. 
Each primary outcome was analysed separately, and all 
analyses were done separately by sex to allow blood 
pressure, its trends, and age associations to diﬀ er among 
outcomes and between men and women.
We calculated mean change in mean blood pressure 
and the prevalence of raised blood pressure across the 
41 years of analysis (reported as change per decade). We 
also report the posterior probability (PP) that an estimated 
trend represents a true increase or decrease. We generated 
age-standardised estimates using the WHO standard 
population,11 by taking weighted means of age–sex-speciﬁ c 
estimates, with use of age weights from the standard 
population. We tested how our statistical model predicted 
mean blood pressure and the prevalence of raised blood 
pressure when a country-year did not have data 
(appendix pp 11–13), which showed that the model 
performed well in its predictive validity.
We calculated the contribution of population growth 
and ageing to the change in the number of adults with 
raised blood pressure by ﬁ xing age-speciﬁ c prevalence at 
its 1975 levels while allowing age-speciﬁ c population to 
change as it did. We calculated the contribution of change 
in prevalence by ﬁ xing age-speciﬁ c population at its 
1975 level while allowing age-speciﬁ c prevalence to 
change as it did. The interaction between the two 
contributions is the residual change in the number of 
adults with raised blood pressure after accounting for the 
two forementioned components.
Role of funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. Country and Regional Data Group members 
and BZ had full access to the data in the study. The 
corresponding author had ﬁ nal responsibility for the 
decision to submit for publication.
Results
We included 1479 population-based measurement surveys 
and studies, with 19·1 million participants aged 18 years 
and older for whom blood pressure was measured. We 
had at least one data source for 174 (87%) of the 
200 countries we made estimates for, covering 97·5% of 
the world’s population in 2015 (appendix pp 193, 194), and 
at least two data sources for 122 (61%) countries. Of these 
1479 sources, 517 (35%) were from national samples, 
249 (17%) covered one or more subnational regions, and 
the remaining 713 (48%) were from one or a small number 
of communities. Regionally, data availability ranged 
from 0·83 data sources per country in central Africa 
to 37 sources per country in high-income Asia Paciﬁ c. 
543 (37%) data sources were from years before 1995 and 
another 936 (63%) were from 1995 and later.
Globally, age-standardised adult mean systolic blood 
pressure remained virtually unchanged from 1975 to 
2015 in men (126·6 mm Hg [95% CrI 124·0 to 129·3] 
in 1975 and 127·0 mm Hg [125·7 to 128·3] in 2015; an 
increase of 0·07 mm Hg per decade [–0·59 to 0·74]; PP of 
being a true increasing trend is 0·5808) and decreased 
slightly in women (123·9 mm Hg [121·3 to 126·6] in 1975 
and 122·3 mm Hg [121·0 to 123·6] in 2015; a decrease of 
0·47 mm Hg per decade [–0·20 to 1·15]; PP=0·9210; 
ﬁ gure 1). Trends in age-standardised mean diastolic 
blood pressure, which was 78·7 mm Hg (77·9 to 79·5) for 
men and 76·7 mm Hg (75·9 to 77·6) for women in 2015, 
were similar (ﬁ gure 2).
Mean systolic and mean diastolic blood pressure 
decreased substantially during these four decades in 
high-income western and high-income Asia Paciﬁ c 
super-regions, moving these two super-regions from 
being among those with the highest blood pressure 
in 1975 to the lowest in 2015 (ﬁ gures 1, 2). The largest 
decrease in mean systolic blood pressure, which occurred 
in high-income Asia Paciﬁ c, was 3·2 mm Hg per decade 
(95% CrI 2·4–3·9) for women and 2·4 mm Hg per decade 
(1·6–3·1) for men (PP>0·9999). The largest decrease in 
mean diastolic blood pressure, which was in the 
high-income western super-region, was 1·8 mm Hg 
per decade (1·4–2·3) for women and 1·5 mm Hg 
per decade (1·0–1·9) for men (PP>0·9999). Mean systolic 
blood pressure also seems to have decreased in women 
in central and eastern Europe, Latin America and the 
Caribbean, and, more recently, central Asia, Middle East, 
and north Africa, but the estimated trends in these 
super-regions had larger uncertainty than those in 
high-income super-regions; mean diastolic blood 
pressure showed a similar, but less pronounced, decrease 
in these super-regions (ﬁ gures 1, 2). Little or no change 
in mean systolic or mean diastolic blood pressure 
occurred in men in these super-regions.
By contrast with these decreases, mean systolic blood 
pressure might have increased in men and women in 
east and southeast Asia, south Asia, Oceania, and 
sub-Saharan Africa, with a similar trend in mean diastolic 
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blood pressure (ﬁ gures 1, 2). Central and eastern Europe, 
sub-Saharan Africa, and south Asia had the highest 
mean blood pressures in 2015.
Age-standardised prevalence of raised blood pressure 
decreased globally from 1975 to 2015, from 
29·5% (95% CrI 24·2–35·0) to 24·1% (21·4–27·1) in 
men (PP=0·9482) and from 26·1% (21·7–31·1) to 
20·1% (17·8–22·5) in women (PP=0·9884). The largest 
decrease was seen in high-income super-regions, 
followed by Latin America and the Caribbean, central 
Figure 1: Trends in age-standardised mean systolic blood pressure by sex and super-region in people aged 18 years and older
The lines show the posterior mean estimates and the shaded areas show the 95% CrI. See appendix (pp 199–266) for trends by country.
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and eastern Europe, and central Asia, Middle East, 
and north Africa (ﬁ gure 3). Elsewhere, age-standardised 
prevalence of raised blood pressure remained 
unchanged. Crude prevalence de creased more 
slowly than age-standardised prevalence, especially 
where there has been substantial ageing (eg, in high-
income super-regions and Latin America and the 
Caribbean).
South Korea and Canada had the lowest age-
standardised mean systolic blood pressure in 2015 for 
Figure 2: Trends in age-standardised mean diastolic blood pressure by sex and super-region in people aged 18 years and older
The lines show the posterior mean estimates and the shaded areas show the 95% CrI. See appendix (pp 199–266) for trends by country.
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both men (117–118 mm Hg) and women (about 
111 mm Hg; ﬁ gure 4). The highest mean systolic blood 
pressures in men were seen in some countries in central 
and eastern Europe (eg, Slovenia, Lithuania, and Croatia), 
Oceania, central Asia, and sub-Saharan Africa, with 
age-standardised mean systolic blood pressure reaching 
137·5 mm Hg (95% CrI 131·2–143·8) in Slovenia. 
Women in a few countries in sub-Saharan Africa 
(eg, Niger, Guinea, Malawi, and Mozambique) had the 
highest levels of mean systolic blood pressure, surpassing 
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Figure 3: Trends in age-standardised and crude prevalence of raised blood pressure by sex and super-region in people aged 18 years and older
The lines show the posterior mean estimates and the shaded area shows the 95% CrI for age-standardised prevalence. See appendix (pp 267–334) for trends by country.
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Figure 4: Age-standardised mean systolic blood pressure, mean diastolic blood pressure, and prevalence of raised blood pressure by sex and country in 2015 in people aged 18 years and older
Interactive versions of these maps and downloadable numerical results are available online.
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132 mm Hg. Countries with the lowest mean diastolic 
blood pressure were Peru and several high-income 
countries including Canada, Australia, the UK, 
New Zealand, and Singapore. Diastolic blood pressure 
was high throughout central and eastern Europe, 
south Asia, and sub-Saharan Africa, with age-standardised 
mean surpassing 85 mm Hg in Lithuanian men. Mean 
systolic and mean diastolic blood pressure were 
correlated across countries (correlation coeﬃ  cients of 
0·69 for men and 0·86 for women in 2015). However, 
men and women in countries in south Asia, central and 
eastern Europe, and central Asia, Middle East, and 
north Africa had higher diastolic blood pressure than 
expected on the basis of their systolic blood pressure and 
the systolic blood pressure–diastolic blood pressure 
association (ﬁ gure 5); the opposite was seen for men and 
women in Oceania.
South Korea, Canada, the USA, Peru, the UK, 
Singapore and Australia had the lowest prevalence of 
raised blood pressure in 2015 for both sexes, with an age-
standardised prevalence of less than 13% in women and 
less than 19% in men (ﬁ gure 4). At the other extreme, 
age-standardised prevalence surpassed 35% in men in 
some countries in central and eastern Europe including 
Croatia, Latvia, Lithuania, Hungary, and Slovenia; 
prevalence was more than 33% in women in a few 
countries in west Africa.
In 2015, men had higher age-standardised mean systolic 
blood pressure than women in most countries (ﬁ gure 6). 
Men also had higher diastolic blood pressure and 
prevalence of raised blood pressure than women in most 
countries, except in sub-Saharan Africa, where the sex 
pattern was reversed in most countries, and a few countries 
in Oceania and Asia. The male–female diﬀ erences in 
age-standardised means and prevalence were virtually all 
due to diﬀ erences in people younger than 50 years; among 
people aged 50 years and older, on average men and 
women had similar mean systolic and diastolic blood 
pressure and prevalence of raised blood pressure, with 
countries divided into some with lower and others with 
higher male blood pressure (results not shown). The 
male–female diﬀ erence in blood pressure in 2015 was 
largest in high-income countries and countries in central 
and eastern Europe. Compared with 1975, the male excess 
in mean blood pressure increased in high-income 
super-regions, central and eastern Europe, Latin America 
and the Caribbean, and central Asia, Middle East, and 
north Africa but decreased (and in the case of diastolic 
blood pressure reversed) in sub-Saharan Africa, Oceania, 
and south Asia (results not shown).
The estimated number of adults with raised blood 
pressure increased from 594 million in 1975 to 1·13 billion 
in 2015 (ﬁ gure 7), comprising 597 million men and 
529 million women. At the global level, this increase was 
attributable to population growth and ageing, oﬀ set 
partly by falling age-speciﬁ c prevalence. In the 
high-income western super-region, the absolute number 
of people with raised blood pressure has decreased 
steadily since 1975 because the steep decrease in 
prevalence outweighed the eﬀ ect of population growth 
and ageing. Nonetheless, 141 million adults in the 
constituent countries had raised blood pressure in 2015. 
Similarly, in central and eastern Europe, the number of 
people with raised blood pressure peaked in 1988 and 
went below its 1975 levels in 2002, driven by decreasing 
prevalence. In high-income Asia Paciﬁ c, the number of 
people with raised blood pressure has decreased since 
2007 but is still higher than it was in 1975. In other 
For interactive maps and 
numerical results see 
www.ncdrisc.org
Figure 5: Relation between age-standardised mean systolic and mean diastolic blood pressure in men and women aged 18 years and older in 2015
The dotted line shows the linear association between the two outcomes. DBP=diastolic blood pressure. SBP=systolic blood pressure.
Sub-Saharan Africa
Central Asia, Middle East, and north Africa
South Asia
East and southeast Asia
High-income Asia Pacific
Oceania
Latin America and Caribbean
High-income western
Central and eastern Europe
70
75
80
85
Ag
e-
st
an
da
rd
ise
d 
m
ea
n 
DB
P 
(m
m
 H
g)
110 115 120 125 130 135
Age-standardised mean SBP (mm Hg) 
Men
110 115 120 125 130 135
Age-standardised mean SBP (mm Hg) 
Women
Articles
www.thelancet.com   Vol 389   January 7, 2017 45
low-income and middle-income super-regions, the 
number of people with raised blood pressure is still 
increasing. In Latin America and the Caribbean and 
central Asia, the Middle East, and north Africa, this rise 
is a net eﬀ ect of increase due to population growth and 
ageing and decrease due to lower age-speciﬁ c prevalence. 
In Oceania, south Asia, east and southeast Asia, and 
sub-Saharan Africa, three quarters or more of the rise is 
attributable to population growth and ageing, and the 
remainder is due to an increase in prevalence (ﬁ gure 7). 
In 2015, 258 million (23%) of the 1·13 billion adults with 
raised blood pressure lived in south Asia (199 million of 
whom in India) and another 235 million (21%) lived in 
east Asia (226 million of whom in China).
Discussion
Raised blood pressure has transitioned from a risk factor 
largely aﬀ ecting high-income countries to one that is 
now most prevalent in low-income countries in 
south Asia and sub-Saharan Africa, while being a 
persistent health issue in central and eastern Europe. 
Although favourable trends continue in high-income 
countries, and might also be happening in some middle-
income regions, other low-income and middle-income 
regions are aﬀ ected by rising, or at best stable but high, 
blood pressure. The number of people with raised blood 
pressure in the world has increased by 90% during these 
four decades, with the majority of the increase occurring 
in low-income and middle-income countries, and largely 
driven by the growth and ageing of the population.
At the global level, we estimated lower mean systolic 
blood pressure in the 1980s, and hence a smaller 
reduction over time, than reported by Danaei and 
colleagues,5 possibly because we had more data than 
their earlier analysis. At the regional level, the additional 
data from low-income and middle-income countries 
included in our analysis gave more conﬁ dence to our 
ﬁ nding of a rise in mean systolic blood pressure in Asia 
and sub-Saharan Africa than the trends estimated by 
Danaei and colleagues.5 Our results cannot be directly 
compared with the studies by Kearney and colleagues12 
and Mills and colleagues13 because these studies included 
people who used antihypertensive medicines when 
calculating prevalence. Despite this diﬀ erence in the 
reported metric, the reports are broadly consistent in 
identifying central and eastern Europe, central Asia, and 
sub-Saharan Africa as regions at the highest risk. Lawes 
and colleagues14 also reported the highest mean systolic 
blood pressure in central and eastern Europe and central 
Asia, as we did, but unlike our study they found lower 
mean systolic blood pressure in south Asia than in most 
regions. This diﬀ erence is largely because blood pressure 
in south Asia has increased since 2000, the reporting 
year of Lawes and colleagues’ study; the diﬀ erence might 
also be attributable to us having substantially more data 
from south Asia than Lawes and colleagues.
The estimated decrease in blood pressure in high-
income countries in our analysis is consistent with 
ﬁ ndings of country studies and the MONICA Project.15–34 
Fewer studies have analysed blood pressure trends in 
low-income and middle-income countries than in high-
income countries. The available studies suggest 
reductions in blood pressure in central and possibly 
eastern Europe,35–38 the Middle East and north Africa,39 
and Latin America,40 and increases in south Asia and 
sub-Saharan Africa,41–43 and possibly in east and 
southeast Asia.44,45
We also found that the prevalence of raised blood 
pressure decreased in some regions where mean blood 
pressure did not change, and remained unchanged 
where the mean increased. Some other studies32,46 have 
also found a larger decrease in the upper tail of blood 
Figure 6: Comparison of age-standardised mean systolic blood pressure, mean diastolic blood pressure, and prevalence of raised blood pressure in men and women aged 18 years and older in 2015
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pressure distribution than in its mean. In the MONICA 
Project,16 the upper percentiles of blood pressure 
distribution decreased more than the mean in some 
communities but not in others. Although the changing 
shape of the distribution is partly due to antihypertensive 
drugs, it has also occurred in younger adult ages when 
medication use is uncommon.32,46 To investigate the 
drivers of the changing distribution would require 
historical data on multiple determinants of blood 
pressure throughout the life course. Finally, our ﬁ nding 
of a higher mean blood pressure in men than in women, 
especially in premenopause ages, is consistent with 
previous studies.47
The strengths of our study include its scope in making 
consistent and comparable estimates of trends in both 
mean and raised blood pressure over four decades for all 
the countries in the world. We used a large amount of 
population-based data covering countries in which more 
than 97% of the global adult population lives. We used 
only data from studies that had measured blood pressure 
to avoid bias in self-reported data. We analysed data 
according to a consistent protocol, and NCD Risk Factor 
Collaboration members veriﬁ ed the characteristics of 
data from each country through repeated checks. We 
pooled data using a statistical model that took into 
account the epidemiological features of blood pressure, 
including non-linear time trends and age associations. 
Our statistical model used all available data while giving 
more weight to national data than to subnational and 
community sources.
Similar to all global analyses, our study is aﬀ ected by 
some limitations. First, some countries had no or few 
data sources, especially those in sub-Saharan Africa and 
the Caribbean. Estimates for these countries relied 
mostly or entirely on the statistical model. The absence 
or scarcity of data is reﬂ ected in wider uncertainty 
intervals of our estimates for these countries and regions, 
emphasising the importance of national NCD-oriented 
surveillance. Second, we had fewer data sources for the 
years before 1990 in most regions, which was reﬂ ected in 
the larger uncertainty for these years. In a sensitivity 
analysis, we analysed trends starting in 1990 with an 
identical model, and compared the post-1990 estimates 
with estimates from the main analysis (which included 
data from 1975 onwards). The estimates were very similar 
with correlation coeﬃ  cients between the estimates from 
the main and sensitivity analyses being 0·94 or higher in 
1990 and 0·98 or higher in 2015 (appendix pp 197, 198). 
Third, only 53% of sources included people older than 
70 years, necessitating the use of data in these older ages 
elsewhere to infer an age pattern and make estimates in 
older ages. In view of the ageing trends throughout the 
world, inclusion of older people in health surveys should 
be emphasised. Fourth, our model accounted and 
adjusted for systematic and random errors in subnational 
and community data. However, the adjustments are not 
country-speciﬁ c because estimation of country-speciﬁ c 
adjustments would require national and subnational or 
community data in the same country and year. Therefore, 
the correction for each single country remains uncertain. 
Fifth, although data held by NCD Risk Factor 
Collaboration members were analysed to provide all the 
primary outcomes, individual participant data could not 
be accessed for 20% of data sources. To overcome this 
issue, we systematically used the reported metrics to 
estimate all of our primary outcomes; the cross-walking 
regressions used for this purpose had good predictive 
accuracy but increased the uncertainty of our estimates. 
Sixth, over time, standard mercury sphygmomanometers 
have been replaced by random-zero sphygmomanometers 
and more recently digital oscillometric devices in health 
surveys. Similarly, studies diﬀ ered on whether they used 
multiple cuﬀ  sizes or one cuﬀ  size. We note that the 
eﬀ ect of measurement device and protocol on population 
mean and prevalence depends on the circumstances of 
each survey. For example, an automated digital device 
with a standard cuﬀ , although not the traditional gold-
standard in a clinical setting, avoids observer bias and 
increases compliance, and possibly even response rate, 
compared with a standard mercury sphygmomanometer 
with multiple cuﬀ s.48 Nonetheless, measurements from 
diﬀ erent devices are not fully comparable,49–51 which 
might have aﬀ ected the estimated trends. When we 
included device type as study-level covariate in our 
statistical model, studies using random-zero 
sphygmomanometers, which were used commonly in 
the late 1980s and 1990s, had lower mean blood pressure 
(by about 4·5 mm Hg for systolic blood pressure and by 
about 3 mm Hg for diastolic blood pressure) and 
prevalence of raised blood pressure than studies using 
standard mercury sphygmomanometers. The mean 
diﬀ erence between studies using digital devices and 
mercury sphygmomanometers was about 2 mm Hg for 
systolic blood pressure and about 0·2 mm Hg for 
diastolic blood pressure. Finally, blood pressure had been 
measured only once in some of our data sources. In 
those sources with multiple measurements, the median 
diﬀ erence between the ﬁ rst measurement and the 
average of subsequent ones was 1·5 mm Hg for systolic 
blood pressure and 0·0 mm Hg for diastolic blood 
pressure, suggesting that mean blood pressure and 
prevalence of raised blood pressure might be slightly 
overestimated in some of our sources.
Blood pressure is a multifaceted trait, aﬀ ected by 
nutrition, environment, and behaviour throughout the 
life course, including fetal and early childhood nutrition 
and growth,52 adiposity,53,54 speciﬁ c components of diet, 
especially sodium and potassium intakes,53 alcohol 
use,54,55 smoking,56 physical activity,54 air pollution,57 lead,58 
noise,59 psychosocial stress, and the use of blood pressure 
lowering drugs. Changes in risk factors and 
improvements in detection and treatment of raised blood 
pressure have, at least partly, resulted in the decrease in 
blood pressure in high-income countries, although the 
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decrease seems to have begun before or in the absence of 
speciﬁ c interventions for risk factors and scale-up of 
treatment, and is only partly accounted for by the 
measured risk factors and treatment.17,19–21,34,35,46,60–70 In 
particular, the decrease in high-income and some 
middle-income countries has happened despite 
increasing body-mass index.71
The partly unexplained nature of these favourable 
trends necessitates speculation about their drivers, which 
might include unmeasured improvements in early 
childhood nutrition and year-round availability of fruits 
and vegetables, which might increase the amount and 
regularity of their consumption. Our results show that 
similar decreasing trends in mean blood pressure and 
prevalence of raised blood pressure might have begun in 
some middle-income regions, although at a slower rate 
than trends in high-income regions, but not in the 
poorest populations, including those in south Asia and 
sub-Saharan Africa, and in populations aﬀ ected by major 
social and economic changes in central and eastern 
Europe. These populations have low consumption of 
fresh fruits72 and, in many cases, high consumption 
of salt.73 South Asia and sub-Saharan Africa have the 
highest prevalence of maternal undernutrition,71,74 
preterm and small-for-gestational age births, and child 
undernutrition;75,76 they have also had some of the 
smallest gains in adult height,74 which is associated with 
lower risk of cardiovascular diseases. Many cases of 
raised blood pressure go untreated in these regions.13,77 
The absence of these favourable determinants of low 
blood pressure, coupled with rising body-mass index,71 
might be causing the increase in mean blood pressure 
in these regions. Therefore, if governments and 
multinational organisations are to address the large and 
inequitable burden of cardiovascular diseases and kidney 
disease associated with high blood pressure, they need to 
take a multifaceted approach using both population-
based strategies throughout the life course and individual 
lifestyle management and treatment through primary 
care systems.78
Contributors
ME designed the study and oversaw research. Members of the Country 
and Regional Data Group collected and reanalysed data, and checked 
pooled data for accuracy of information about their study and other 
studies in their country. BZ and MDC led data collection. BZ and JB led 
the statistical analysis. BZ prepared results. Members of the Pooled 
Analysis and Writing Group collated data, checked all data sources in 
consultation with the Country and Regional Data Group, analysed 
pooled data, and prepared results. BZ and ME wrote the ﬁ rst draft of the 
report with input from other members of the Pooled Analysis and 
Writing Group. Members of the Country and Regional Data Group 
commented on the draft report.
NCD Risk Factor Collaboration (NCD-RisC)
Pooled Analysis and Writing (* equal contribution)—Bin Zhou (Imperial 
College London, UK); James Bentham (Imperial College London, UK)*; 
Mariachiara Di Cesare (Middlesex University, UK)*; Honor Bixby 
(Imperial College London, UK); Goodarz Danaei (Harvard T H Chan 
School of Public Health, USA); Melanie J Cowan (World Health 
Organization, Switzerland); Christopher J Paciorek (University of 
California, Berkeley, USA); Gitanjali Singh (Tufts University, USA); 
Kaveh Hajifathalian (Harvard T H Chan School of Public Health, USA); 
James E Bennett (Imperial College London, UK); Cristina Taddei 
(Imperial College London, UK); Ver Bilano (Imperial College London, 
UK); Rodrigo M Carrillo-Larco (Universidad Peruana Cayetano Heredia, 
Peru); Shirin Djalalinia (Tehran University of Medical Sciences, Iran); 
Shahab Khatibzadeh (Brandeis University, USA); Charles Lugero 
(Mulago Hospital, Uganda); Niloofar Peykari (Tehran University of 
Medical Sciences, Iran); Wan Zhu Zhang (Mulago Hospital, Uganda); 
Yuan Lu (Yale University, USA); Gretchen A Stevens (World Health 
Organization, Switzerland); Leanne M Riley (World Health 
Organization, Switzerland); Pascal Bovet (University of Lausanne, 
Switzerland; Ministry of Health, Seychelles); Prof Paul Elliott (Imperial 
College London, UK); Prof Dongfeng Gu (National Center for 
Cardiovascular Diseases, China); Nayu Ikeda (National Institute of 
Health and Nutrition, Japan); Prof Rod T Jackson (University of 
Auckland, New Zealand); Prof Michel Joﬀ res (Simon Fraser University, 
Canada); Prof Andre Pascal Kengne (South African Medical Research 
Council, South Africa); Prof Tiina Laatikainen (National Institute for 
Health and Welfare, Finland); Prof Tai Hing Lam (University of Hong 
Kong, China); Prof Avula Laxmaiah (National Institute of Nutrition, 
India); Jing Liu (Capital Medical University Beijing An Zhen Hospital, 
China); J Jaime Miranda (Universidad Peruana Cayetano Heredia, Peru); 
Prof Charles K Mondo (Mulago Hospital, Uganda); 
Hannelore K Neuhauser (Robert Koch Institute, Germany); 
Prof Johan Sundström (Uppsala University, Sweden); Prof Liam Smeeth 
(London School of Hygiene & Tropical Medicine, UK); Maroje Sorić 
(University of Zagreb, Croatia); Prof Mark Woodward (University of 
Sydney, Australia; University of Oxford, UK); Prof Majid Ezzati (Imperial 
College London, UK)
Country and Regional Data (* equal contribution; listed alphabetically)—
Leandra Abarca-Gómez (Caja Costarricense de Seguro Social, Costa 
Rica)*; Ziad A Abdeen (Al-Quds University, Palestine)*; 
Hanan Abdul Rahim (Qatar University, Qatar)*; Niveen M Abu-Rmeileh 
(Birzeit University, Palestine)*; Benjamin Acosta-Cazares (Instituto 
Mexicano del Seguro Social, Mexico)*; Robert Adams (The University of 
Adelaide, Australia)*; Wichai Aekplakorn (Mahidol University, 
Thailand)*; Kaosar Afsana (BRAC, Bangladesh)*; 
Carlos A Aguilar-Salinas (Instituto Nacional de Ciencias Médicas y 
Nutricion, Mexico)*; Charles Agyemang (University of Amsterdam, 
Netherlands)*; Alireza Ahmadvand (Non-Communicable Diseases 
Research Center, Iran)*; Wolfgang Ahrens (Leibniz Institute for 
Prevention Research and Epidemiology—BIPS, Germany)*; 
Rajaa Al Raddadi (Ministry of Health, Saudi Arabia)*; Rihab Al Woyatan 
(Ministry of Health, Kuwait)*; Mohamed M Ali (World Health 
Organization Regional Oﬃ  ce for the Eastern Mediterranean, Egypt)*; 
Ala’a Alkerwi (Luxembourg Institute of Health, Luxembourg)*; 
Eman Aly (World Health Organization Regional Oﬃ  ce for the Eastern 
Mediterranean, Egypt)*; Philippe Amouyel (Lille University and 
Hospital, France)*; Antoinette Amuzu (London School of Hygiene & 
Tropical Medicine, UK)*; Lars Bo Andersen (Sogn and Fjordane 
University College, Norway)*; Sigmund A Anderssen (Norwegian 
School of Sport Sciences, Norway)*; Lars Ängquist (Bispebjerg and 
Frederiksberg Hospitals, Denmark)*; Ranjit Mohan Anjana (Madras 
Diabetes Research Foundation, India)*; Daniel Ansong (Komfo Anokye 
Teaching Hospital, Ghana)*; Hajer Aounallah-Skhiri (National Institute 
of Public Health, Tunisia)*; Joana Araújo (University of Porto, 
Portugal)*; Inger Ariansen (Norwegian Institute of Public Health, 
Norway)*; Tahir Aris (Ministry of Health Malaysia, Malaysia)*; 
Nimmathota Arlappa (National Institute of Nutrition, India)*; 
Krishna Aryal (Nepal Health Research Council, Nepal)*; 
Dominique Arveiler (Strasbourg University and Hospital, France)*; 
Felix K Assah (University of Yaoundé 1, Cameroon)*; 
Maria Cecília F Assunção (Federal University of Pelotas, Brazil)*; 
Mária Avdicová (Regional Authority of Public Health, Banska Bystrica, 
Slovakia)*; Ana Azevedo (University of Porto Medical School, 
Portugal)*; Fereidoun Azizi (Shahid Beheshti University of Medical 
Sciences, Iran)*; Bontha V Babu (Indian Council of Medical Research, 
India)*; Suhad Bahijri (King Abdulaziz University, Saudi Arabia)*; 
Nagalla Balakrishna (National Institute of Nutrition, India)*; 
Piotr Bandosz (Medical University of Gdansk, Poland)*; José R Banegas 
(Universidad Autónoma de Madrid, Spain)*; Carlo M Barbagallo 
Articles
www.thelancet.com   Vol 389   January 7, 2017 49
(University of Palermo, Italy)*; Alberto Barceló (Pan American Health 
Organization, USA)*; Amina Barkat (Université Mohammed V de 
Rabat, Morocco)*; Aluisio J D Barros (Federal University of Pelotas, 
Brazil)*; Mauro V Barros (University of Pernambuco, Brazil)*; 
Iqbal Bata (Dalhousie University, Canada)*; Anwar M Batieha (Jordan 
University of Science and Technology, Jordan)*; Louise A Baur 
(University of Sydney, Australia)*; Robert Beaglehole (University of 
Auckland, New Zealand)*; Habiba Ben Romdhane (University Tunis El 
Manar, Tunisia)*; Mikhail Benet (University Medical Science, Cuba)*; 
Lowell S Benson (University of Utah School of Medicine, USA)*; 
Antonio Bernabe-Ortiz (Universidad Peruana Cayetano Heredia, Peru)*; 
Gailute Bernotiene (Lithuanian University of Health Sciences, 
Lithuania)*; Heloisa Bettiol (University of São Paulo, Brazil)*; 
Aroor Bhagyalaxmi (B J Medical College, India)*; Sumit Bharadwaj 
(Chirayu Medical College, India)*; Santosh K Bhargava (SL Jain 
Hospital, India)*; Yufang Bi (Shanghai Jiao-Tong University School of 
Medicine, China)*; Mukharram Bikbov (Ufa Eye Research Institute, 
Russia)*; Peter Bjerregaard (University of Southern Denmark, 
Denmark; University of Greenland, Greenland)*; Espen Bjertness 
(University of Oslo, Norway)*; Cecilia Björkelund (University of 
Gothenburg, Sweden)*; Anneke Blokstra (National Institute for Public 
Health and the Environment, Netherlands)*; Simona Bo (University of 
Turin, Italy)*; Martin Bobak (University College London, UK)*; 
Heiner Boeing (German Institute of Human Nutrition, Germany)*; 
Jose G Boggia (Universidad de la República, Uruguay)*; 
Carlos P Boissonnet (CEMIC, Argentina)*; Vanina Bongard (Toulouse 
University School of Medicine, France)*; Pascal Bovet (University of 
Lausanne, Switzerland; Ministry of Health, Seychelles)*; 
Lutgart Braeckman (Ghent University, Belgium)*; Imperia Brajkovich 
(Universidad Central de Venezuela, Venezuela)*; Francesco Branca 
(World Health Organization, Switzerland)*; Juergen Breckenkamp 
(Bielefeld University, Germany)*; Hermann Brenner (German Cancer 
Research Center, Germany)*; Lizzy M Brewster (University of 
Amsterdam, Netherlands)*; Graziella Bruno (University of Turin, 
Italy)*; H B(as) Bueno-de-Mesquita (National Institute for Public Health 
and the Environment, Netherlands)*; Anna Bugge (University of 
Southern Denmark, Denmark)*; Con Burns (Cork Institute of 
Technology, Ireland)*; Michael Bursztyn (Hadassah-Hebrew University 
Medical Center, Israel)*; Antonio Cabrera de León (Universidad de La 
Laguna, Spain)*; Joseph Cacciottolo (University of Malta, Malta)*; 
Christine Cameron (Canadian Fitness and Lifestyle Research Institute, 
Canada)*; Günay Can (Istanbul University, Turkey)*; 
Ana Paula C Cândido (Universidade Federal de Juiz de Fora, Brazil)*; 
Vincenzo Capuano (Cardiologia di Mercato S Severino, Italy)*; 
Viviane C Cardoso (University of São Paulo, Brazil)*; Axel C Carlsson 
(Karolinska Institutet, Sweden)*; Maria J Carvalho (University of Porto, 
Portugal)*; Felipe F Casanueva (Santiago de Compostela University, 
Spain)*; Juan-Pablo Casas (University College London, UK)*; 
Carmelo A Caserta (Associazione Calabrese di Epatologia, Italy)*; 
Snehalatha Chamukuttan (India Diabetes Research Foundation, 
India)*; Angelique W Chan (Duke-NUS Medical School, Singapore)*; 
Queenie Chan (Imperial College London, UK)*; 
Himanshu K Chaturvedi (National Institute of Medical Statistics, 
India)*; Nishi Chaturvedi (University College London, UK)*; 
Chien-Jen Chen (Academia Sinica, Taiwan)*; Fangfang Chen (Capital 
Institute of Pediatrics, China)*; Huashuai Chen (Duke University, 
USA)*; Shuohua Chen (Kailuan General Hospital, China)*; 
Zhengming Chen (University of Oxford, UK)*; Ching-Yu Cheng 
(Duke-NUS Medical School, Singapore)*; Imane Cherkaoui Dekkaki 
(Université Mohammed V de Rabat, Morocco)*; Angela Chetrit (The 
Gertner Institute for Epidemiology and Health Policy Research, Israel)*; 
Arnaud Chiolero (Lausanne University Hospital, Switzerland)*; 
Shu-Ti Chiou (Ministry of Health and Welfare, Taiwan)*; 
Adela Chirita-Emandi (Victor Babeș University of Medicine and 
Pharmacy Timisoara, Romania)*; Belong Cho (Seoul National 
University College of Medicine, South Korea)*; Yumi Cho (Korea 
Centers for Disease Control and Prevention, South Korea)*; 
Jerzy Chudek (Medical University of Silesia, Poland)*; Renata Cifkova 
(Charles University in Prague, Czech Republic)*; Frank Claessens 
(Katholieke Universiteit Leuven, Belgium)*; Els Clays (Ghent 
University, Belgium)*; Hans Concin (Agency for Preventive and Social 
Medicine, Austria)*; Cyrus Cooper (University of Southampton, UK)*; 
Rachel Cooper (University College London, UK)*; Tara C Coppinger 
(Cork Institute of Technology, Ireland)*; Simona Costanzo (IRCCS 
Istituto Neurologico Mediterraneo Neuromed, Italy)*; Dominique Cottel 
(Institut Pasteur de Lille, France)*; Chris Cowell (Westmead University 
of Sydney, Australia)*; Cora L Craig (Canadian Fitness and Lifestyle 
Research Institute, Canada)*; Ana B Crujeiras (CIBEROBN, Spain)*; 
Juan J Cruz (Universidad Autónoma de Madrid, Spain)*; 
Graziella D’Arrigo (National Council of Research, Italy)*; 
Eleonora d’Orsi (Federal University of Santa Catarina, Brazil)*; 
Jean Dallongeville (Institut Pasteur de Lille, France)*; 
Albertino Damasceno (Eduardo Mondlane University, Mozambique)*; 
Goodarz Danaei (Harvard T H Chan School of Public Health, USA)*; 
Rachel Dankner (The Gertner Institute for Epidemiology and Health 
Policy Research, Israel)*; Thomas M Dantoft (Research Centre for 
Prevention and Health, Denmark)*; Luc Dauchet (Lille University 
Hospital, France)*; Guy De Backer (Ghent University, Belgium)*; Dirk 
De Bacquer (Ghent University, Belgium)*; Giovanni de Gaetano (IRCCS 
Istituto Neurologico Mediterraneo Neuromed, Italy)*; 
Stefaan De Henauw (Ghent University, Belgium)*; Delphine De Smedt 
(Ghent University, Belgium)*; Mohan Deepa (Madras Diabetes 
Research Foundation, India)*; Abbas Dehghan (Erasmus Medical 
Center Rotterdam, Netherlands)*; Hélène Delisle (University of 
Montreal, Canada)*; Valérie Deschamps (French Public Health Agency, 
France)*; Klodian Dhana (Erasmus Medical Center Rotterdam, 
Netherlands)*; Augusto F Di Castelnuovo (IRCCS Istituto Neurologico 
Mediterraneo Neuromed, Italy)*; Juvenal Soares Dias-da-Costa 
(Universidade do Vale do Rio dos Sinos, Brazil)*; Alejandro Diaz 
(National Council of Scientiﬁ c and Technical Research, Argentina)*; 
Ty T Dickerson (University of Utah School of Medicine, USA)*; 
Shirin Djalalinia (Non-Communicable Diseases Research Center, 
Iran)*; Ha T P Do (National Institute of Nutrition, Vietnam)*; 
Annette J Dobson (University of Queensland, Australia)*; 
Chiara Donfrancesco (Istituto Superiore di Sanità, Italy)*; 
Silvana P Donoso (Universidad de Cuenca, Ecuador)*; Angela Döring 
(Helmholtz Zentrum München, Germany)*; Kouamelan Doua 
(Ministère de la Santé et de la Lutte Contre le Sida, Côte d’Ivoire)*; 
Wojciech Drygas (The Cardinal Wyszynski Institute of Cardiology, 
Poland)*; Virginija Dulskiene (Lithuanian University of Health 
Sciences, Lithuania)*; Aleksandar Džakula (University of Zagreb, 
Croatia)*; Vilnis Dzerve (University of Latvia, Latvia)*; 
Elzbieta Dziankowska-Zaborszczyk (Medical University of Łodz, 
Poland)*; Robert Eggertsen (University of Gothenburg, Sweden)*; 
Ulf Ekelund (Norwegian School of Sport Sciences, Norway)*; 
Jalila El Ati (National Institute of Nutrition and Food Technology, 
Tunisia)*; Ute Ellert (Robert Koch Institute, Germany)*; Paul Elliott 
(Imperial College London, UK)*; Roberto Elosua (Institut Hospital del 
Mar d’Investigacions Mèdiques, Spain)*; Rajiv T Erasmus (University of 
Stellenbosch, South Africa)*; Cihangir Erem (Karadeniz Technical 
University, Turkey)*; Louise Eriksen (University of Southern Denmark, 
Denmark)*; Jorge Escobedo-de la Peña (Instituto Mexicano del Seguro 
Social, Mexico)*; Alun Evans (The Queen’s University of Belfast, UK)*; 
David Faeh (University of Zurich, Switzerland)*; Caroline H Fall 
(University of Southampton, UK)*; Farshad Farzadfar (Tehran 
University of Medical Sciences, Iran)*; Francisco J Felix-Redondo 
(Centro de Salud Villanueva Norte, Spain)*; Trevor S Ferguson (The 
University of the West Indies, Jamaica)*; Daniel Fernández-Bergés 
(Hospital Don Benito-Villanueva de la Serena, Spain)*; Daniel Ferrante 
(Ministry of Health, Argentina)*; Marika Ferrari (Council for 
Agricultural Research and Economics, Italy)*; Catterina Ferreccio 
(Pontiﬁ cia Universidad Católica de Chile, Chile)*; Jean Ferrieres 
(Toulouse University School of Medicine, France)*; Joseph D Finn 
(University of Manchester, UK)*; Krista Fischer (University of Tartu, 
Estonia)*; Bernhard Föger (Agency for Preventive and Social Medicine, 
Austria)*; Leng Huat Foo (Universiti Sains Malaysia, Malaysia)*; 
Ann-Soﬁ e Forslund (Umeå University, Sweden)*; Maria Forsner 
(Dalarna University, Sweden)*; Stephen P Fortmann (Stanford 
University, USA)*; Heba M Fouad (World Health Organization Regional 
Oﬃ  ce for the Eastern Mediterranean, Egypt)*; Damian K Francis 
(The University of the West Indies, Jamaica)*; Maria do Carmo Franco 
(Federal University of São Paulo, Brazil)*; Oscar H Franco (Erasmus 
Articles
50 www.thelancet.com   Vol 389   January 7, 2017
Medical Center Rotterdam, Netherlands)*; Guillermo Frontera (Hospital 
Universitario Son Espases, Spain)*; Flavio D Fuchs (Hospital de 
Clinicas de Porto Alegre, Brazil)*; Sandra C Fuchs (Universidade 
Federal do Rio Grande do Sul, Brazil)*; Yuki Fujita (Kindai University, 
Japan)*; Takuro Furusawa (Kyoto University, Japan)*; Zbigniew Gaciong 
(Medical University of Warsaw, Poland)*; Dickman Gareta (University 
of KwaZulu-Natal, South Africa)*; Sarah P Garnett (University of 
Sydney, Australia)*; Jean-Michel Gaspoz (Geneva University Hospitals, 
Switzerland)*; Magda Gasull (CIBER en Epidemiología y Salud Pública, 
Spain)*; Louise Gates (Australian Bureau of Statistics, Australia)*; 
Diana Gavrila (Murcia Regional Health Council, Spain)*; 
Johanna M Geleijnse (Wageningen University, Netherlands)*; 
Anoosheh Ghasemian (Endocrinology and Metabolism Research 
Institute, Iran)*; Anup Ghimire (B P Koirala Institute of Health 
Sciences, Nepal)*; Simona Giampaoli (Istituto Superiore di Sanità, 
Italy)*; Francesco Gianfagna (University of Insubria, Italy)*; 
Jonathan Giovannelli (Lille University Hospital, France)*; 
Rebecca A Goldsmith (Ministry of Health, Israel)*; Helen Gonçalves 
(Federal University of Pelotas, Brazil)*; Marcela Gonzalez Gross 
(Universidad Politécnica de Madrid, Spain)*; Juan P González Rivas 
(The Andes Clinic of Cardio-Metabolic Studies, Venezuela)*; 
Frederic Gottrand (Université de Lille 2, France)*; Sidsel Graﬀ -Iversen 
(Norwegian Institute of Public Health, Norway)*; Dušan Grafnetter 
(Institute for Clinical and Experimental Medicine, Czech Republic)*; 
Aneta Grajda (The Children’s Memorial Health Institute, Poland)*; 
Ronald D Gregor (Dalhousie University, Canada)*; Tomasz Grodzicki 
(Jagiellonian University Medical College, Poland)*; Anders Grøntved 
(University of Southern Denmark, Denmark)*; Grabriella Gruden 
(University of Turin, Italy)*; Vera Grujic (University of Novi Sad, 
Serbia)*; Dongfeng Gu (National Center for Cardiovascular Diseases, 
China)*; Ong Peng Guan (Singapore Eye Research Institute, 
Singapore)*; Vilmundur Gudnason (University of Iceland, Iceland)*; 
Ramiro Guerrero (Universidad Icesi, Colombia)*; Idris Guessous 
(Geneva University Hospitals, Switzerland)*; Andre L Guimaraes (State 
University of Montes Claros, Brazil)*; Martin C Gulliford (King’s 
College London, UK)*; Johanna Gunnlaugsdottir (Icelandic Heart 
Association, Iceland)*; Marc Gunter (Imperial College London, UK)*; 
Prakash C Gupta (Healis-Sekhsaria Institute for Public Health, India)*; 
Oye Gureje (University of Ibadan, Nigeria)*; Beata Gurzkowska (The 
Children’s Memorial Health Institute, Poland)*; Laura Gutierrez 
(Institute for Clinical Eﬀ ectiveness and Health Policy, Argentina)*; 
Felix Gutzwiller (University of Zurich, Switzerland)*; Farzad Hadaegh 
(Shahid Beheshti University of Medical Sciences, Iran)*; Jytte Halkjær 
(Danish Cancer Society Research Centre, Denmark)*; Ian R Hambleton 
(The University of the West Indies, Barbados)*; Rebecca Hardy 
(University College London, UK)*; Rachakulla Harikumar (National 
Institute of Nutrition, India)*; Jun Hata (Kyushu University, Japan)*; 
Alison J Hayes (University of Sydney, Australia)*; Jiang He (Tulane 
University, USA)*; Marleen Elisabeth Hendriks (Academic Medical 
Center Amsterdam, Netherlands)*; Ana Henriques (University of Porto, 
Portugal)*; Leticia Hernandez Cadena (National Institute of Public 
Health, Mexico)*; Herqutanto (Universitas Indonesia, Indonesia)*; 
Sauli Herrala (Oulu University Hospital, Finland)*; Ramin Heshmat 
(Chronic Diseases Research Center, Iran)*; Ilpo Tapani Hihtaniemi 
(Imperial College London, UK)*; Sai Yin Ho (University of Hong Kong, 
China)*; Suzanne C Ho (The Chinese University of Hong Kong, 
China)*; Michael Hobbs (University of Western Australia, Australia)*; 
Albert Hofman (Erasmus Medical Center Rotterdam, Netherlands)*; 
Gonul Horasan Dinc (Celal Bayar University, Turkey)*; 
Claudia M Hormiga (Fundación Oftalmológica de Santander, 
Colombia)*; Bernardo L Horta (Universidade Federal de Pelotas, 
Brazil)*; Leila Houti (University of Oran 1, Algeria)*; Christina Howitt 
(The University of the West Indies, Barbados)*; Thein Thein Htay 
(University of Public Health, Myanmar)*; Aung Soe Htet (Ministry of 
Health, Myanmar)*; Yonghua Hu (Peking University, China)*; 
José María Huerta (CIBER en Epidemiología y Salud Pública, Spain)*; 
Abdullatif S Husseini (Birzeit University, Palestine)*; Inge Huybrechts 
(International Agency for Research on Cancer, France)*; Nahla Hwalla 
(American University of Beirut, Lebanon)*; Licia Iacoviello (IRCCS 
Istituto Neurologico Mediterraneo Neuromed, Italy)*; Anna G Iannone 
(Cardiologia di Mercato S. Severino, Italy)*; M Mohsen Ibrahim (Cairo 
University, Egypt)*; Nayu Ikeda (National Institute of Health and 
Nutrition, Japan)*; M Arfan Ikram (Erasmus Medical Center Rotterdam, 
Netherlands)*; Vilma E Irazola (Institute for Clinical Eﬀ ectiveness and 
Health Policy, Argentina)*; Muhammad Islam (Aga Khan University, 
Pakistan)*; Vanja Ivkovic (UHC Zagreb, Croatia)*; Masanori Iwasaki 
(Niigata University, Japan)*; Rod T Jackson (University of Auckland, 
New Zealand)*; Jeremy M Jacobs (Hadassah University Medical Center, 
Israel)*; Tazeen Jafar (Duke-NUS Medical School, Singapore)*; 
Konrad Jamrozik (University of Adelaide, Australia; deceased)*; 
Imre Janszky (Norwegian University of Science and Technology, 
Norway)*; Grazyna Jasienska (Jagiellonian University Medical College, 
Poland)*; Bojan Jelakovic (University of Zagreb School of Medicine, 
Croatia)*; Chao Qiang Jiang (Guangzhou 12th Hospital, China)*; 
Michel Joﬀ res (Simon Fraser University, Canada)*; Mattias Johansson 
(International Agency for Research on Cancer, France)*; Jost B Jonas 
(Ruprecht-Karls-University of Heidelberg, Germany)*; 
Torben Jørgensen (Research Centre for Prevention and Health, 
Denmark)*; Pradeep Joshi (World Health Organization Country Oﬃ  ce, 
India)*; Anne Juolevi (National Institute for Health and Welfare, 
Finland)*; Gregor Jurak (University of Ljubljana, Slovenia)*; 
Vesna Jureša (University of Zagreb, Croatia)*; Rudolf Kaaks (German 
Cancer Research Center, Germany)*; Anthony Kafatos (University of 
Crete, Greece)*; Ofra Kalter-Leibovici (The Gertner Institute for 
Epidemiology and Health Policy Research, Israel)*; Nor Azmi 
Kamaruddin (Universiti Kebangsaan Malaysia, Malaysia)*; 
Amir Kasaeian (Tehran University of Medical Sciences, Iran)*; 
Joanne Katz (Johns Hopkins Bloomberg School of Public Health, 
USA)*; Jussi Kauhanen (University of Eastern Finland, Finland)*; 
Prabhdeep Kaur (National Institute of Epidemiology, India)*; 
Maryam Kavousi (Erasmus Medical Center Rotterdam, Netherlands)*; 
Gyulli Kazakbaeva (Ufa Eye Research Institute, Russia)*; Ulrich Keil 
(University of Münster, Germany)*; Lital Keinan Boker (Israel Center 
for Disease Control, Israel)*; Sirkka Keinänen-Kiukaanniemi (Oulu 
University Hospital, Finland)*; Roya Kelishadi (Research Institute for 
Primordial Prevention of Non-Communicable Disease, Iran)*; 
Han C G Kemper (VU University Medical Center, Netherlands)*; 
Andre Pascal Kengne (South African Medical Research Council, South 
Africa)*; Mathilde Kersting (Research Institute of Child Nutrition, 
Germany)*; Timothy Key (University of Oxford, UK)*; 
Yousef Saleh Khader (Jordan University of Science and Technology, 
Jordan)*; Davood Khalili (Shahid Beheshti University of Medical 
Sciences, Iran)*; Young-Ho Khang (Seoul National University, South 
Korea)*; Kay-Tee Khaw (University of Cambridge, UK)*; Stefan Kiechl 
(Medical University of Innsbruck, Austria)*; Japhet Killewo (Muhimbili 
University of Health and Allied Sciences, Tanzania)*; Jeongseon Kim 
(National Cancer Center, South Korea)*; Jurate Klumbiene (Lithuanian 
University of Health Sciences, Lithuania)*; Elin Kolle (Norwegian 
School of Sport Sciences, Norway)*; Patrick Kolsteren (Institute of 
Tropical Medicine, Belgium)*; Paul Korrovits (Tartu University Clinics, 
Estonia)*; Seppo Koskinen (National Institute for Health and Welfare, 
Finland)*; Katsuyasu Kouda (Kindai University, Japan)*; 
Slawomir Koziel (Polish Academy of Sciences Anthropology Unit in 
Wroclaw, Poland)*; Peter Lund Kristensen (University of Southern 
Denmark, Denmark)*; Steinar Krokstad (Norwegian University of 
Science and Technology, Norway)*; Daan Kromhout (University of 
Groningen, Netherlands)*; Herculina S Kruger (North-West University, 
South Africa)*; Ruzena Kubinova (National Institute of Public Health, 
Czech Republic)*; Renata Kuciene (Lithuanian University of Health 
Sciences, Lithuania)*; Diana Kuh (University College London, UK)*; 
Urho M Kujala (University of Jyväskylä, Finland)*; Krzysztof Kula 
(Medical University of Łodz, Poland)*; Zbigniew Kulaga (The Children’s 
Memorial Health Institute, Poland)*; R Krishna Kumar (Amrita 
Institute of Medical Sciences, India)*; Pawel Kurjata (The Cardinal 
Wyszynski Institute of Cardiology, Poland)*; Yadlapalli S Kusuma (All 
India Institute of Medical Sciences, India)*; Kari Kuulasmaa (National 
Institute for Health and Welfare, Finland)*; Catherine Kyobutungi 
(African Population and Health Research Center, Kenya)*; 
Tiina Laatikainen (National Institute for Health and Welfare, Finland)*; 
Carl Lachat (Ghent University, Belgium)*; Tai Hing Lam (University of 
Hong Kong, China)*; Orlando Landrove (Ministerio de Salud Pública, 
Cuba)*; Vera Lanska (Institute for Clinical and Experimental Medicine, 
Articles
www.thelancet.com   Vol 389   January 7, 2017 51
Czech Republic)*; Georg Lappas (Sahlgrenska Academy, Sweden)*; 
Bagher Larijani (Endocrinology and Metabolism Research Center, 
Iran)*; Lars E Laugsand (Norwegian University of Science and 
Technology, Norway)*; Avula Laxmaiah (National Institute of Nutrition, 
India)*; Khanh Le Nguyen Bao (National Institute of Nutrition, 
Vietnam)*; Tuyen D Le (National Institute of Nutrition, Vietnam)*; 
Catherine Leclercq (Food and Agriculture Organization, Italy)*; 
Jeannette Lee (National University of Singapore, Singapore)*; 
Jeonghee Lee (National Cancer Center, South Korea)*; Terho Lehtimäki 
(Tampere University Hospital, Finland)*; Rampal Lekhraj (Universiti 
Putra Malaysia, Malaysia)*; Luz M León-Muñoz (Universidad Autónoma 
de Madrid, Spain)*; Naomi S Levitt (University of Cape Town, South 
Africa)*; Yanping Li (Harvard T H Chan School of Public Health, 
USA)*; Christa L Lilly (West Virginia University, USA)*; Wei-Yen Lim 
(National University of Singapore, Singapore)*; M Fernanda Lima-Costa 
(Oswaldo Cruz Foundation Rene Rachou Research Institute, Brazil)*; 
Hsien-Ho Lin (National Taiwan University, Taiwan)*; Xu Lin (University 
of Chinese Academy of Sciences, China)*; Allan Linneberg (Research 
Centre for Prevention and Health, Denmark)*; Lauren Lissner 
(University of Gothenburg, Sweden)*; Mieczyslaw Litwin (The 
Children’s Memorial Health Institute, Poland)*; Jing Liu (Capital 
Medical University Beijing An Zhen Hospital, China)*; Roberto Lorbeer 
(University Medicine Greifswald, Germany)*; Paulo A Lotufo 
(University of São Paulo, Brazil)*; José Eugenio Lozano (Consejería de 
Sanidad Junta de Castilla y León, Spain)*; Dalia Luksiene (Lithuanian 
University of Health Sciences, Lithuania)*; Annamari Lundqvist 
(National Institute for Health and Welfare, Finland)*; Nuno Lunet 
(Universidade do Porto, Portugal)*; Per Lytsy (University of Uppsala, 
Sweden)*; Guansheng Ma (Peking University, China)*; Jun Ma (Peking 
University, China)*; George L L Machado-Coelho (Universidade Federal 
de Ouro Preto, Brazil)*; Suka Machi (The Jikei University School of 
Medicine, Japan)*; Stefania Maggi (National Research Council, Italy)*; 
Dianna J Magliano (Baker IDI Heart and Diabetes Institute, Australia)*; 
Marjeta Majer (University of Zagreb, Croatia)*; Marcia Makdisse 
(Hospital Israelita Albert Einstein, Brazil)*; Reza Malekzadeh (Tehran 
University of Medical Sciences, Iran)*; Rahul Malhotra (Duke-NUS 
Medical School, Singapore)*; Kodavanti Mallikharjuna Rao (National 
Institute of Nutrition, India)*; Soﬁ a Malyutina (Institute of Internal and 
Preventive Medicine, Russia)*; Yannis Manios (Harokopio University, 
Greece)*; Jim I Mann (University of Otago, New Zealand)*; 
Enzo Manzato (University of Padova, Italy)*; Paula Margozzini 
(Pontiﬁ cia Universidad Católica de Chile, Chile)*; Pedro Marques-Vidal 
(Lausanne University Hospital, Switzerland)*; Jaume Marrugat (Institut 
Hospital del Mar d’Investigacions Mèdiques, Spain)*; 
Reynaldo Martorell (Emory University, USA)*; Ellisiv B Mathiesen (UiT 
The Arctic University of Norway, Norway)*; Alicia Matijasevich 
(University of São Paulo, Brazil)*; Tandi E Matsha (Cape Peninsula 
University of Technology, South Africa)*; Jean Claude N Mbanya 
(University of Yaoundé 1, Cameroon)*; Anselmo J Mc Donald Posso 
(Gorgas Memorial Institute of Health Studies, Panama)*; 
Shelly R McFarlane (The University of the West Indies, Jamaica)*; 
Stephen T McGarvey (Brown University, USA)*; Stela McLachlan 
(University of Edinburgh, UK)*; Rachael M McLean (University of 
Otago, New Zealand)*; Breige A McNulty (University College Dublin, 
Ireland)*; Amir Sharifuddin Md Khir (Penang Medical College, 
Malaysia)*; Sounnia Mediene-Benchekor (University of Oran 1, 
Algeria)*; Jurate Medzioniene (Lithuanian University of Health 
Sciences, Lithuania)*; Aline Meirhaeghe (Institut National de la Santé 
et de la Recherche Médicale, France)*; Christa Meisinger (Helmholtz 
Zentrum München, Germany)*; Ana Maria B Menezes (Federal 
University of Pelotas, Brazil)*; Geetha R Menon (Indian Council of 
Medical Research, India)*; Indrapal I Meshram (National Institute of 
Nutrition, India)*; Andres Metspalu (University of Tartu, Estonia)*; 
Jie Mi (Capital Institute of Pediatrics, China)*; Kairit Mikkel (University 
of Tartu, Estonia)*; Jody C Miller (University of Otago, New Zealand)*; 
Juan Francisco Miquel (Pontiﬁ cia Universidad Católica de Chile, 
Chile)*; J Jaime Miranda (Universidad Peruana Cayetano Heredia, 
Peru)*; Marjeta Mišigoj-Durakovic (University of Zagreb, Croatia)*; 
Mostafa K Mohamed (Ain Shams University, Egypt)*; 
Kazem Mohammad (Tehran University of Medical Sciences, Iran)*; 
Noushin Mohammadifard (Hypertension Research Center, Iran)*; 
Viswanathan Mohan (Madras Diabetes Research Foundation, India)*; 
Muhammad Fadhli Mohd Yusoﬀ  (Ministry of Health Malaysia, 
Malaysia)*; Niels C Møller (University of Southern Denmark, 
Denmark)*; Dénes Molnár (University of Pécs, Hungary)*; 
Amirabbas Momenan (Shahid Beheshti University of Medical Sciences, 
Iran)*; Charles K Mondo (Mulago Hospital, Uganda)*; 
Kotsedi Daniel K Monyeki (University of Limpopo, South Africa)*; 
Leila B Moreira (Universidade Federal do Rio Grande do Sul, Brazil)*; 
Alain Morejon (University Medical Science, Cuba)*; Luis A Moreno 
(Universidad de Zaragoza, Spain)*; Karen Morgan (RCSI Dublin, 
Ireland)*; George Moschonis (Harokopio University, Greece)*; 
Malgorzata Mossakowska (International Institute of Molecular and Cell 
Biology, Poland)*; Aya Mostafa (Ain Shams University, Egypt)*; 
Jorge Mota (University of Porto, Portugal)*; 
Mohammad Esmaeel Motlagh (Ahvaz Jundishapur University of 
Medical Sciences, Iran)*; Jorge Motta (Gorgas Memorial Institute of 
Public Health, Panama)*; Maria L Muiesan (University of Brescia, 
Italy)*; Martina Müller-Nurasyid (Helmholtz Zentrum München, 
Germany)*; Neil Murphy (Imperial College London, UK)*; 
Jaakko Mursu (University of Eastern Finland, Finland)*; Vera Musil 
(University of Zagreb, Croatia)*; Gabriele Nagel (Ulm University, 
Germany)*; Balkish M Naidu (Institute of Public Health, Malaysia)*; 
Harunobu Nakamura (Kobe University, Japan)*; Jana Námešná 
(Regional Authority of Public Health, Banska Bystrica, Slovakia)*; 
Ei Ei K Nang (National University of Singapore, Singapore)*; 
Vinay B Nangia (Suraj Eye Institute, India)*; Sameer Narake 
(Healis-Sekhsaria Institute for Public Health, India)*; 
Eva Maria Navarrete-Muñoz (CIBER en Epidemiología y Salud Pública, 
Spain)*; Ndeye Coumba Ndiaye (INSERM, France)*; William A Neal 
(West Virginia University, USA)*; Ilona Nenko (Jagiellonian University 
Medical College, Poland)*; Flavio Nervi (Pontiﬁ cia Universidad Católica 
de Chile, Chile)*; Hannelore K Neuhauser (Robert Koch Institute, 
Germany)*; Nguyen D Nguyen (The University of Pharmacy and 
Medicine of Ho Chi Minh City, Vietnam)*; Quang Ngoc Nguyen (Hanoi 
Medical University, Vietnam)*; Ramﬁ s E Nieto-Martínez (Universidad 
Centro-Occidental Lisandro Alvarado, Venezuela)*; Teemu J Niiranen 
(National Institute for Health and Welfare, Finland)*; Guang Ning 
(Shanghai Jiao-Tong University School of Medicine, China)*; 
Toshiharu Ninomiya (Kyushu University, Japan)*; Sania Nishtar 
(Heartﬁ le, Pakistan)*; Marianna Noale (National Research Council, 
Italy)*; Oscar A Noboa (Universidad de la República, Uruguay)*; 
Ahmad Ali Noorbala (Tehran University of Medical Sciences, Iran)*; 
Teresa Norat (Imperial College London, UK)*; Davide Noto (University 
of Palermo, Italy)*; Mohannad Al Nsour (Eastern Mediterranean Public 
Health Network, Jordan)*; Dermot O’Reilly (The Queen’s University of 
Belfast, UK)*; Kyungwon Oh (Korea Centers for Disease Control and 
Prevention, South Korea)*; Maria Teresa A Olinto (Universidade do Vale 
do Rio dos Sinos, Brazil)*; Isabel O Oliveira (Federal University of 
Pelotas, Brazil)*; Mohd Azahadi Omar (Ministry of Health Malaysia, 
Malaysia)*; Altan Onat (Istanbul University, Turkey)*; Pedro Ordunez 
(Pan American Health Organization, USA)*; Clive Osmond (University 
of Southampton, UK)*; Sergej M Ostojic (University of Novi Sad, 
Serbia)*; Johanna A Otero (Fundación Oftalmológica de Santander, 
Colombia)*; Kim Overvad (Aarhus University, Denmark)*; 
Ellis Owusu-Dabo (Kwame Nkrumah University of Science and 
Technology, Ghana)*; Fred Michel Paccaud (Institute for Social and 
Preventive Medicine, Switzerland)*; Cristina Padez (University of 
Coimbra, Portugal)*; Elena Pahomova (University of Latvia, Latvia)*; 
Andrzej Pajak (Jagiellonian University Medical College, Poland)*; 
Domenico Palli (Cancer Prevention and Research Institute, Italy)*; 
Luigi Palmieri (Istituto Superiore di Sanità, Italy)*; 
Songhomitra Panda-Jonas (Ruprecht-Karls-University of Heidelberg, 
Germany)*; Francesco Panza (University of Bari, Italy)*; 
Dimitrios Papandreou (Zayed University, UAE)*; Winsome R Parnell 
(University of Otago, New Zealand)*; Mahboubeh Parsaeian (Tehran 
University of Medical Sciences, Iran)*; Ivan Pecin (University of Zagreb 
School of Medicine, Croatia)*; Mangesh S Pednekar (Healis-Sekhsaria 
Institute for Public Health, India)*; Nasheeta Peer (South African 
Medical Research Council, South Africa)*; Petra H Peeters (University 
Medical Center Utrecht, Netherlands)*; Sergio Viana Peixoto (Oswaldo 
Cruz Foundation Rene Rachou Research Institute, Brazil)*; 
Articles
52 www.thelancet.com   Vol 389   January 7, 2017
Catherine Pelletier (Public Health Agency of Canada, Canada)*; 
Markku Peltonen (National Institute for Health and Welfare, Finland)*; 
Alexandre C Pereira (Heart Institute, Brazil)*; Rosa Marina Pérez 
(National Institute of Hygiene, Epidemiology and Microbiology, Cuba)*; 
Annette Peters (Helmholtz Zentrum München, Germany)*; 
Janina Petkeviciene (Lithuanian University of Health Sciences, 
Lithuania)*; Niloofar Peykari (Non-Communicable Diseases Research 
Center, Iran)*; Son Thai Pham (Vietnam National Heart Institute, 
Vietnam)*; Iris Pigeot (Leibniz Institute for Prevention Research and 
Epidemiology—BIPS, Germany)*; Hynek Pikhart (University College 
London, UK)*; Aida Pilav (Federal Ministry of Health, Bosnia and 
Herzegovina)*; Lorenza Pilotto (Cardiovascular Prevention Centre 
Udine, Italy)*; Freda Pitakaka (University of New South Wales, 
Australia)*; Pedro Plans-Rubió (Public Health Agency of Catalonia, 
Spain)*; Maria Polakowska (The Cardinal Wyszynski Institute of 
Cardiology, Poland)*; Ozren Polašek (University of Split, Croatia)*; 
Miquel Porta (Institut Hospital del Mar d’Investigacions Mèdiques, 
Spain)*; Marileen LP Portegies (Erasmus Medical Center Rotterdam, 
Netherlands)*; Akram Pourshams (Tehran University of Medical 
Sciences, Iran)*; Rajendra Pradeepa (Madras Diabetes Research 
Foundation, India)*; Mathur Prashant (Indian Council of Medical 
Research, India)*; Jacqueline F Price (University of Edinburgh, UK)*; 
Maria Puiu (Victor Babeș University of Medicine and Pharmacy 
Timisoara, Romania)*; Margus Punab (Tartu University Clinics, 
Estonia)*; Radwan F Qasrawi (Al-Quds University, Palestine)*; 
Mostafa Qorbani (Alborz University of Medical Sciences, Iran)*; 
Ivana Radic (University of Novi Sad, Serbia)*; Ricardas Radisauskas 
(Lithuanian University of Health Sciences, Lithuania)*; 
Mahfuzar Rahman (BRAC, Bangladesh)*; Olli Raitakari (Turku 
University Hospital, Finland)*; Manu Raj (Amrita Institute of Medical 
Sciences, India)*; Sudha Ramachandra Rao (National Institute of 
Epidemiology, India)*; Ambady Ramachandran (India Diabetes 
Research Foundation, India)*; Elisabete Ramos (University of Porto 
Medical School, Portugal)*; Sanjay Rampal (Julius Centre University of 
Malaya, Malaysia)*; Daniel A Rangel Reina (Gorgas Memorial Institute 
of Health Studies, Panama)*; Finn Rasmussen (Karolinska Institutet, 
Sweden)*; Josep Redon (University of Valencia, Spain)*; 
Paul Ferdinand M Reganit (University of the Philippines, Philippines)*; 
Robespierre Ribeiro (Minas Gerais State Secretariat for Health, Brazil)*; 
Elio Riboli (Imperial College London, UK)*; Fernando Rigo (Health 
Center San Agustín, Spain)*; Tobias F Rinke de Wit (PharmAccess 
Foundation, Netherlands)*; Raphael M Ritti-Dias (Hospital Israelita 
Albert Einstein, Brazil)*; Sian M Robinson (University of Southampton, 
UK)*; Cynthia Robitaille (Public Health Agency of Canada, Canada)*; 
Fernando Rodríguez-Artalejo (Universidad Autónoma de Madrid, 
Spain)*; María del Cristo Rodriguez-Perez (Canarian Health Service, 
Spain)*; Laura A Rodríguez-Villamizar (Universidad Industrial de 
Santander, Colombia)*; Rosalba Rojas-Martinez (Instituto Nacional de 
Salud Pública, Mexico)*; Annika Rosengren (University of Gothenburg, 
Sweden)*; Adolfo Rubinstein (Institute for Clinical Eﬀ ectiveness and 
Health Policy, Argentina)*; Ornelas Rui (University of Madeira, 
Portugal)*; Blanca Sandra Ruiz-Betancourt (Instituto Mexicano del 
Seguro Social, Mexico)*; Andrea R V Russo Horimoto (Heart Institute, 
Brazil)*; Marcin Rutkowski (Medical University of Gdansk, Poland)*; 
Charumathi Sabanayagam (Singapore Eye Research Institute, 
Singapore)*; Harshpal S Sachdev (Sitaram Bhartia Institute of Science 
and Research, India)*; Olfa Saidi (University Tunis El Manar, Tunisia)*; 
Sibel Sakarya (Marmara University, Turkey)*; Benoit Salanave (French 
Public Health Agency, France)*; Eduardo Salazar Martinez (National 
Institute of Public Health, Mexico)*; Diego Salmerón (CIBER en 
Epidemiología y Salud Pública, Spain)*; Veikko Salomaa (National 
Institute for Health and Welfare, Finland)*; Jukka T Salonen (University 
of Helsinki, Finland)*; Massimo Salvetti (University of Brescia, Italy)*; 
Jose Sánchez-Abanto (National Institute of Health, Peru)*; Susana Sans 
(Catalan Department of Health, Spain)*; Diana Santos (Universidade de 
Lisboa, Portugal)*; Ina S Santos (Federal University of Pelotas, Brazil)*; 
Renata Nunes dos Santos (University of Sao Paulo Clinics Hospital, 
Brazil)*; Rute Santos (University of Porto, Portugal)*; Jouko L Saramies 
(South Karelia Social and Health Care District, 
Finland)*; Luis B Sardinha (Universidade de Lisboa, Portugal)*; 
Giselle Sarganas Margolis (Robert Koch Institut, Germany)*; 
Nizal Sarrafzadegan (Isfahan Cardiovascular Research Center, Iran)*; 
Kai-Uwe Saum (German Cancer Research Center, Germany)*; 
Savvas C Savva (Research and Education Institute of Child Health, 
Cyprus)*; Marcia Scazufca (University of Sao Paulo Clinics Hospital, 
Brazil)*; Herman Schargrodsky (Hospital Italiano de Buenos Aires, 
Argentina)*; Ione J Schneider (Federal University of Santa Catarina, 
Brazil)*; Constance Schultsz (Academic Medical Center Amsterdam, 
Netherlands)*; Aletta E Schutte (South African Medical Research 
Council, South Africa; North-West University, South Africa)*; 
Abhijit Sen (Norwegian University of Science and Technology, 
Norway)*; Idowu O Senbanjo (Lagos State University College of 
Medicine, Nigeria)*; Sadaf G Sepanlou (Digestive Diseases Research 
Institute, Iran)*; Sanjib K Sharma (B P Koirala Institute of Health 
Sciences, Nepal)*; Jonathan E Shaw (Baker IDI Heart and Diabetes 
Institute, Australia)*; Kenji Shibuya (The University of Tokyo, Japan)*; 
Dong Wook Shin (Seoul National University College of Medicine, South 
Korea)*; Youchan Shin (Singapore Eye Research Institute, Singapore)*; 
Rosalynn Siantar (Singapore Eye Research Institute, Singapore)*; 
Abla M Sibai (American University of Beirut, Lebanon)*; 
Diego Augusto Santos Silva (Federal University of Santa Catarina, 
Brazil)*; Mary Simon (India Diabetes Research Foundation, India)*; 
Judith Simons (St Vincent’s Hospital, Australia)*; Leon A Simons 
(University of New South Wales, Australia)*; Michael Sjöström 
(Karolinska Institutet, Sweden)*; Sine Skovbjerg (Research Centre for 
Prevention and Health, Denmark)*; Jolanta Slowikowska-Hilczer 
(Medical University of Łodz, Poland)*; Przemyslaw Slusarczyk 
(International Institute of Molecular and Cell Biology, Poland)*; 
Liam Smeeth (London School of Hygiene & Tropical Medicine, UK)*; 
Margaret C Smith (University of Oxford, UK)*; Marieke B Snijder 
(Academic Medical Center Amsterdam, Netherlands)*; Hung-Kwan So 
(The Chinese University of Hong Kong, China)*; Eugène Sobngwi 
(University of Yaoundé 1, Cameroon)*; Stefan Söderberg (Umeå 
University, Sweden)*; Vincenzo Solfrizzi (University of Bari, Italy)*; 
Emily Sonestedt (Lund University, Sweden)*; Yi Song (Peking 
University, China)*; Thorkild IA Sørensen (University of Copenhagen, 
Denmark)*; Maroje Soric (University of Zagreb, Croatia)*; 
Charles Sossa Jérome (Institut Régional de Santé Publique, Benin)*; 
Aicha Soumare (University of Bordeaux, France)*; Jan A Staessen 
(University of Leuven, Belgium)*; Gregor Starc (University of Ljubljana, 
Slovenia)*; Maria G Stathopoulou (INSERM, France)*; Bill Stavreski 
(Heart Foundation, Australia)*; Jostein Steene-Johannessen (Norwegian 
School of Sport Sciences, Norway)*; Peter Stehle (Bonn University, 
Germany)*; Aryeh D Stein (Emory University, USA)*; 
George S Stergiou (Sotiria Hospital, Greece)*; Jochanan Stessman 
(Hadassah University Medical Center, Israel)*; Jutta Stieber (Helmholtz 
Zentrum München, Germany)*; Doris Stöckl (Helmholtz Zentrum 
München, Germany)*; Tanja Stocks (Lund University, Sweden)*; 
Jakub Stokwiszewski (National Institute of Public Health-National 
Institute of Hygiene, Poland)*; Karien Stronks (University of 
Amsterdam, Netherlands)*; Maria Wany Strufaldi (Federal University of 
São Paulo, Brazil)*; Chien-An Sun (Fu Jen Catholic University, 
Taiwan)*; Johan Sundström (Uppsala University, Sweden)*; Yn-Tz Sung 
(The Chinese University of Hong Kong, China)*; 
Paibul Suriyawongpaisal (Mahidol University, Thailand)*; Rody G Sy 
(University of the Philippines, Philippines)*; E Shyong Tai (National 
University of Singapore, Singapore)*; Mari-Liis Tammesoo (University 
of Tartu, Estonia)*; Abdonas Tamosiunas (Lithuanian University of 
Health Sciences, Lithuania)*; Line Tang (Research Centre for 
Prevention and Health, Denmark)*; Xun Tang (Peking University, 
China)*; Frank Tanser (University of KwaZulu-Natal, South Africa)*; 
Yong Tao (Peking University, China)*; Mohammed Rasoul Tarawneh 
(Ministry of Health, Jordan)*; Carolina B Tarqui-Mamani (National 
Institute of Health, Peru)*; Anne Taylor (The University of Adelaide, 
Australia)*; Holger Theobald (Karolinska Institutet, Sweden)*; 
Lutgarde Thijs (University of Leuven, Belgium)*; Betina H Thuesen 
(Research Centre for Prevention and Health, Denmark)*; 
Anne Tjonneland (Danish Cancer Society Research Centre, Denmark)*; 
Hanna K Tolonen (National Institute for Health and Welfare, Finland)*; 
Janne S Tolstrup (University of Southern Denmark, Denmark)*; 
Murat Topbas (Karadeniz Technical University, Turkey)*; 
Roman Topór-Madry (Jagiellonian University Medical College, Poland)*; 
Articles
www.thelancet.com   Vol 389   January 7, 2017 53
María José Tormo (Murcia Regional Health Council, Spain)*; 
Maties Torrent (IB-SALUT Area de Salut de Menorca, Spain)*; 
Pierre Traissac (Institut de Recherche pour le Développement, France)*; 
Dimitrios Trichopoulos (Harvard T H Chan School of Public Health, 
USA, deceased)*; Antonia Trichopoulou (Hellenic Health Foundation, 
Greece)*; Oanh T H Trinh (The University of Pharmacy and Medicine 
of Ho Chi Minh City, Vietnam)*; Atul Trivedi (Government Medical 
College, India)*; Lechaba Tshepo (Sefako Makgatho Health Science 
University, South Africa)*; Marshall K Tulloch-Reid (The University of 
the West Indies, Jamaica)*; Tomi-Pekka Tuomainen (University of 
Eastern Finland, Finland)*; Jaakko Tuomilehto (Dasman Diabetes 
Institute, Kuwait)*; Maria L Turley (Ministry of Health, New Zealand)*; 
Per Tynelius (Karolinska Institutet, Sweden)*; Christophe Tzourio 
(University of Bordeaux, France)*; Peter Ueda (Harvard T H Chan 
School of Public Health, USA)*; Eunice Ugel (Universidad Centro-
Occidental Lisandro Alvarado, Venezuela)*; Hanno Ulmer (Medical 
University of Innsbruck, Austria)*; Hannu M T Uusitalo (University of 
Tampere Tays Eye Center, Finland)*; Gonzalo Valdivia (Pontiﬁ cia 
Universidad Católica de Chile, Chile)*; Damaskini Valvi (Harvard T H 
Chan School of Public Health, USA)*; Yvonne T van der Schouw 
(University Medical Center Utrecht, Netherlands)*; Koen Van Herck 
(Ghent University, Belgium)*; Lenie van Rossem (University Medical 
Center Utrecht, Netherlands)*; Irene GM van Valkengoed (Academic 
Medical Center Amsterdam, Netherlands)*; Dirk Vanderschueren 
(Katholieke Universiteit Leuven, Belgium)*; Diego Vanuzzo (Centro di 
Prevenzione Cardiovascolare Udine, Italy)*; Lars Vatten (Norwegian 
University of Science and Technology, Norway)*; Tomas Vega 
(Consejería de Sanidad Junta de Castilla y León, Spain)*; 
Gustavo Velasquez-Melendez (Universidade Federal de Minas Gerais, 
Brazil)*; Giovanni Veronesi (University of Insubria, Italy)*; 
W M Monique Verschuren (National Institute for Public Health and the 
Environment, Netherlands)*; Roosmarijn Verstraeten (Institute of 
Tropical Medicine, Belgium)*; Cesar G Victora (Universidade Federal de 
Pelotas, Brazil)*; Lucie Viet (National Institute for Public Health and the 
Environment, Netherlands)*; Eira Viikari-Juntura (Finnish Institute of 
Occupational Health, Finland)*; Paolo Vineis (Imperial College London, 
UK)*; Jesus Vioque (Universidad Miguel Hernandez, Spain)*; 
Jyrki K Virtanen (University of Eastern Finland, Finland)*; 
Sophie Visvikis-Siest (INSERM, France)*; Bharathi Viswanathan 
(Ministry of Health, Seychelles)*; Peter Vollenweider (Lausanne 
University Hospital, Switzerland)*; Sari Voutilainen (University of 
Eastern Finland, Finland)*; Ana Vrdoljak (UHC Zagreb, Croatia)*; 
Martine Vrijheid (Centre for Research in Environmental Epidemiology, 
Spain)*; Alisha N Wade (University of the Witwatersrand, South 
Africa)*; Aline Wagner (University of Strasbourg, France)*; 
Janette Walton (University College Cork, Ireland)*; 
Wan Nazaimoon Wan Mohamud (Institute for Medical Research, 
Malaysia)*; Ming-Dong Wang (Public Health Agency of Canada, 
Canada)*; Qian Wang (Xinjiang Medical University, China)*; 
Ya Xing Wang (Beijing Tongren Hospital, China)*; 
S Goya Wannamethee (University College London, UK)*; 
Nicholas Wareham (University of Cambridge, UK)*; Niels Wederkopp 
(University of Southern Denmark, Denmark)*; Deepa Weerasekera 
(Ministry of Health, New Zealand)*; Peter H Whincup (St George’s, 
University of London, UK)*; Kurt Widhalm (Medical University of 
Vienna, Austria)*; Indah S Widyahening (Universitas Indonesia, 
Indonesia)*; Andrzej Wiecek (Medical University of Silesia, Poland)*; 
Alet H Wijga (National Institute for Public Health and the 
Environment, Netherlands)*; Rainford J Wilks (The University of the 
West Indies, Jamaica)*; Johann Willeit (Medical University of 
Innsbruck, Austria)*; Peter Willeit (Medical University of Innsbruck, 
Austria)*; Emmanuel A Williams (Komfo Anokye Teaching Hospital, 
Ghana)*; Tom Wilsgaard (UiT The Arctic University of Norway, 
Norway)*; Bogdan Wojtyniak (National Institute of Public Health-
National Institute of Hygiene, Poland)*; Tien Yin Wong (Duke-NUS 
Medical School, Singapore)*; Roy A Wong-McClure (Caja Costarricense 
de Seguro Social, Costa Rica)*; Jean Woo (The Chinese University of 
Hong Kong, China)*; Mark Woodward (University of Sydney, Australia; 
University of Oxford, UK)*; Aleksander Giwercman Wu (Lund 
University, Sweden)*; Frederick C Wu (University of Manchester, UK)*; 
Shou Ling Wu (Kailuan General Hospital, China)*; Haiquan Xu 
(Institute of Food and Nutrition Development of Ministry of 
Agriculture, China)*; Weili Yan (Children’s Hospital of Fudan 
University, China)*; Xiaoguang Yang (Chinese Center for Disease 
Control and Prevention, China)*; Xingwang Ye (University of Chinese 
Academy of Sciences, China)*; Panayiotis K Yiallouros (University of 
Cyprus, Cyprus)*; Akihiro Yoshihara (Niigata University, Japan)*; 
Novie O Younger-Coleman (The University of the West Indies, 
Jamaica)*; Ahmad F Yusoﬀ  (Ministry of Health, Malaysia)*; 
Muhammad Fadhli M Yusoﬀ  (Institute of Public Health, Malaysia)*; 
Sabina Zambon (University of Padova, Italy)*; Tomasz Zdrojewski 
(Medical University of Gdansk, Poland)*; Yi Zeng (Duke University, 
USA; Peking University, China)*; Dong Zhao (Capital Medical 
University Beijing An Zhen Hospital, China)*; Wenhua Zhao (Chinese 
Center for Disease Control and Prevention, China)*; Yingﬀ eng Zheng 
(Singapore Eye Research Institute, Singapore)*; Dan Zhu (Inner 
Mongolia Medical University, China)*; Esther Zimmermann 
(Bispebjerg and Frederiksberg Hospitals, Denmark)*; 
Julio Zuñiga Cisneros (Gorgas Memorial Institute of Public Health, 
Panama)*
Declaration of interests
ME reports a charitable grant from the Youth Health Programme of 
AstraZeneca, outside the submitted work. LS reports personal fees from 
GlaxoSmithKline and AstraZeneca, outside the submitted work and is a 
trustee of the British Heart Foundation. JS reports personal fees from 
Iterim, outside the submitted work. MW reports personal fees from 
Amgen, outside the submitted work.
Acknowledgments
We thank Christina Banks, Dheeya Rizmie, and Yasaman Vali for 
assistance with data extraction. We thank WHO country and regional 
oﬃ  ces and the World Heart Federation for support in data identiﬁ cation 
and access. The authors alone are responsible for the views expressed in 
this Article and they do not necessarily represent the views, decisions, or 
policies of the institutions with which they are aﬃ  liated.
References
1 Global Burden of Metabolic Risk Factors for Chronic Diseases 
Collaboration. Cardiovascular disease, chronic kidney disease, and 
diabetes mortality burden of cardiometabolic risk factors from 
1980 to 2010: a comparative risk assessment. 
Lancet Diabetes Endocrinol 2014; 2: 634–47.
2 WHO. Global action plan for the prevention and control of 
noncommunicable diseases 2013–2020. 2013. http://apps.who.int/
iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1 
(accessed Aug 14, 2015).
3 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective 
Studies Collaboration. Age-speciﬁ c relevance of usual blood pressure 
to vascular mortality: a meta-analysis of individual data for one million 
adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
4 Czernichow S, Zanchetti A, Turnbull F, et al. The eﬀ ects of blood 
pressure reduction and of diﬀ erent blood pressure-lowering 
regimens on major cardiovascular events according to baseline 
blood pressure: meta-analysis of randomized trials. J Hypertens 
2011; 29: 4–16.
5 Danaei G, Finucane MM, Lin JK, et al. National, regional, and 
global trends in systolic blood pressure since 1980: systematic 
analysis of health examination surveys and epidemiological studies 
with 786 country-years and 5·4 million participants. Lancet 2011; 
377: 568–77.
6 Rose G, Day S. The population mean predicts the number of 
deviant individuals. BMJ 1990; 301: 1031–34.
7 Finucane MM, Paciorek CJ, Danaei G, Ezzati M. 
Bayesian estimation of population-level trends in measures of 
health status. Stat Sci 2014; 29: 18–25.
8 NCD Risk Factor Collaboration. Worldwide trends in diabetes 
since 1980: a pooled analysis of 751 population-based studies with 
4.4 million participants. Lancet 2016; 387: 1513–30.
9 Singh GM, Danaei G, Pelizzari PM, et al. The age associations of 
blood pressure, cholesterol, and glucose: analysis of health 
examination surveys from international populations. Circulation 
2012; 125: 2204–11.
10 Rodriguez BL, Labarthe DR, Huang B, Lopez-Gomez J. Rise of 
blood pressure with age. New evidence of population diﬀ erences. 
Hypertension 1994; 24: 779–85.
Articles
54 www.thelancet.com   Vol 389   January 7, 2017
11 Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, 
Inoue M. Age standardization of rates: a new WHO standard. 
Geneva: World Health Organization, 2001.
12 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, 
He J. Global burden of hypertension: analysis of worldwide data. 
Lancet 2005; 365: 217–23.
13 Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension 
prevalence and control: a systematic analysis of population-based 
studies from 90 countries. Circulation 2016; 134: 441–50.
14 Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, 
Rodgers A. Blood pressure and the global burden of disease 2000. 
Part 1: estimates of blood pressure levels. J Hypertens 2006; 24: 413–22.
15 Evans A, Tolonen H, Hense HW, et al. Trends in coronary risk 
factors in the WHO MONICA project. Int J Epidemiol 2001; 
30 (suppl 1): S35–40.
16 Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, 
Kuulasmaa K. Pattern of declining blood pressure across replicate 
population surveys of the WHO MONICA project, mid-1980s to 
mid-1990s, and the role of medication. BMJ 2006; 332: 629–35.
17 McCarron P, Smith GD, Okasha M. Secular changes in blood 
pressure in childhood, adolescence and young adulthood: 
systematic review of trends from 1948 to 1998. J Hum Hypertens 
2002; 16: 677–89.
18 Bennett SA, Magnus P. Trends in cardiovascular risk factors in 
Australia. Results from the National Heart Foundation’s Risk Factor 
Prevalence Study, 1980–1989. Med J Aust 1994; 161: 519–27.
19 Joossens JV, Kesteloot H. Trends in systolic blood pressure, 24-hour 
sodium excretion, and stroke mortality in the elderly in Belgium. 
Am J Med 1991; 90: 5–11S.
20 Ikeda N, Gakidou E, Hasegawa T, Murray CJ. Understanding the 
decline of mean systolic blood pressure in Japan: an analysis of 
pooled data from the National Nutrition Survey, 1986–2002. 
Bull World Health Organ 2008; 86: 978–88.
21 Ueshima H, Tatara K, Asakura S, Okamoto M. Declining trends in 
blood pressure level and the prevalence of hypertension, and changes 
in related factors in Japan, 1956–1980. J Chronic Dis 1987; 40: 137–47.
22 Wietlisbach V, Paccaud F, Rickenbach M, Gutzwiller F. Trends in 
cardiovascular risk factors (1984–1993) in a Swiss region: results of 
three population surveys. Prev Med 1997; 26: 523–33.
23 Tverdal A. Signiﬁ cant decline in blood pressure levels after 
1996—fact or artefact? Tidsskr Nor Laegeforen 2001; 121: 1821–25 (in 
Norwegian).
24 Kastarinen MJ, Nissinen AM, Vartiainen EA, et al. Blood pressure 
levels and obesity trends in hypertensive and normotensive Finnish 
population from 1982 to 1997. J Hypertens 2000; 18: 255–62.
25 Juonala M, Viikari JS, Hutri-Kahonen N, et al. The 21-year follow-up 
of the Cardiovascular Risk in Young Finns Study: risk factor levels, 
secular trends and east-west diﬀ erence. J Intern Med 2004; 
255: 457–68.
26 Nuotio J, Oikonen M, Magnussen CG, et al. Cardiovascular risk 
factors in 2011 and secular trends since 2007: the Cardiovascular 
Risk in Young Finns Study. Scand J Public Health 2014; 42: 563–71.
27 Borodulin K, Vartiainen E, Peltonen M, et al. Forty-year trends in 
cardiovascular risk factors in Finland. Eur J Public Health 2015; 
25: 539–46.
28 Pereira M, Carreira H, Vales C, Rocha V, Azevedo A, Lunet N. 
Trends in hypertension prevalence (1990–2005) and mean blood 
pressure (1975–2005) in Portugal: a systematic review. Blood Press 
2012; 21: 220–26.
29 Giampaoli S, Palmieri L, Donfrancesco C, Lo Noce C, Pilotto L, 
Vanuzzo D. Cardiovascular health in Italy. Ten-year surveillance of 
cardiovascular diseases and risk factors: Osservatorio 
Epidemiologico Cardiovascolare/Health Examination Survey 
1998–2012. Eur J Prev Cardiol 2015; 22 (suppl 2): 9–37.
30 Hoﬀ meister H, Mensink GB, Stolzenberg H, et al. Reduction of 
coronary heart disease risk factors in the German cardiovascular 
prevention study. Prev Med 1996; 25: 135–45.
31 Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular 
mortality eﬀ ects of state-level blood pressure and uncontrolled 
hypertension in the United States. Circulation 2008; 117: 905–14.
32 Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, 
awareness, treatment, and control of hypertension in the adult US 
population. Data from the health examination surveys, 1960 to 1991. 
Hypertension 1995; 26: 60–69.
33 Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, 
management, and control of hypertension among United States 
adults, 1999 to 2010. J Am Coll Cardiol 2012; 60: 599–606.
34 Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension 
management in England: a serial cross-sectional study from 
1994 to 2011. Lancet 2014; 383: 1912–19.
35 Cifkova R, Skodova Z, Bruthans J, et al. Longitudinal trends in 
major cardiovascular risk factors in the Czech population between 
1985 and 2007/8. Czech MONICA and Czech post-MONICA. 
Atherosclerosis 2010; 211: 676–81.
36 Vlasoﬀ  T, Laatikainen T, Korpelainen V, et al. Ten year trends in 
chronic disease risk factors in the Republic of Karelia, Russia. 
Eur J Public Health 2008; 18: 666–73.
37 Abina J, Volozh O, Solodkaya E, Saava M. Blood pressure and 
contributing factors in inhabitants of Estonia: 15-year trends. 
Blood Press 2003; 12: 111–21.
38 Dorobantu M, Darabont R, Ghiorghe S, et al. Hypertension 
prevalence and control in Romania at a seven-year interval. 
Comparison of SEPHAR I and II surveys. J Hypertens 2014; 32: 39–47.
39 Sozmen K, Unal B, Saidi O, et al. Cardiovascular risk factor trends 
in the Eastern Mediterranean region: evidence from four countries 
is alarming. Int J Public Health 2015; 60 (suppl 1): S3–11.
40 Picon RV, Fuchs FD, Moreira LB, Riegel G, Fuchs SC. Trends in 
prevalence of hypertension in Brazil: a systematic review with 
meta-analysis. PLoS One 2012; 7: e48255.
41 Fezeu L, Kengne AP, Balkau B, Awah PK, Mbanya JC. 
Ten-year change in blood pressure levels and prevalence of 
hypertension in urban and rural Cameroon. 
J Epidemiol Community Health 2010; 64: 360–65.
42 Gupta R, al-Odat NA, Gupta VP. Hypertension epidemiology in 
India: meta-analysis of 50 year prevalence rates and blood pressure 
trends. J Hum Hypertens 1996; 10: 465–72.
43 Gupta R. Trends in hypertension epidemiology in India. 
J Hum Hypertens 2004; 18: 73–78.
44 Nguyen QN, Pham ST, Nguyen VL, et al. Time trends in blood 
pressure, body mass index and smoking in the Vietnamese 
population: a meta-analysis from multiple cross-sectional surveys. 
PLoS One 2012; 7: e42825.
45 Guo J, Zhu YC, Chen YP, Hu Y, Tang XW, Zhang B. The dynamics 
of hypertension prevalence, awareness, treatment, control and 
associated factors in Chinese adults: results from CHNS 1991–2011. 
J Hypertens 2015; 33: 1688–96.
46 Goﬀ  DC, Howard G, Russell GB, Labarthe DR. Birth cohort 
evidence of population inﬂ uences on blood pressure in the 
United States, 1887–1994. Ann Epidemiol 2001; 11: 271–79.
47 Reckelhoﬀ  JF. Gender diﬀ erences in the regulation of blood 
pressure. Hypertension 2001; 37: 1199–208.
48 Myers MG, Godwin M, Dawes M, et al. Conventional versus 
automated measurement of blood pressure in primary care patients 
with systolic hypertension: randomised parallel design controlled 
trial. BMJ 2011; 342: d286.
49 Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood 
pressure measurement in humans and experimental animals: 
part 1: blood pressure measurement in humans: a statement for 
professionals from the Subcommittee of Professional and Public 
Education of the American Heart Association Council on High 
Blood Pressure Research. Circulation 2005; 111: 697–716.
50 Ogedegbe G, Pickering T. Principles and techniques of blood 
pressure measurement. Cardiol Clin 2010; 28: 571–86.
51 O’Brien E, Waeber B, Parati G, Staessen J, Myers MG. 
Blood pressure measuring devices: recommendations of the 
European Society of Hypertension. BMJ 2001; 322: 531–36.
52 Victora CG, Adair L, Fall C, et al. Maternal and child undernutrition: 
consequences for adult health and human capital. Lancet 2008; 
371: 340–57.
53 Sacks FM, Campos H. Dietary therapy in hypertension. 
N Engl J Med 2010; 362: 2102–12.
54 Institute of Medicine. A population-based policy and systems 
change approach to prevent and control hypertension. Washington, 
DC: The National Academies Press, 2010.
55 Taylor B, Irving HM, Baliunas D, et al. Alcohol and hypertension: 
gender diﬀ erences in dose-response relationships determined 
through systematic review and meta-analysis. Addiction 2009; 
104: 1981–90.
Articles
www.thelancet.com   Vol 389   January 7, 2017 55
56 Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. 
Cigarette smoking and hypertension. Curr Pharm Des 2010; 
16: 2518–25.
57 Liang R, Zhang B, Zhao X, Ruan Y, Lian H, Fan Z. Eﬀ ect of 
exposure to PM2.5 on blood pressure: a systematic review and 
meta-analysis. J Hypertens 2014; 32: 2130–40.
58 Navas-Acien A, Schwartz BS, Rothenberg SJ, Hu H, Silbergeld EK, 
Guallar E. Bone lead levels and blood pressure endpoints: 
a meta-analysis. Epidemiology 2008; 19: 496–504.
59 van Kempen E, Babisch W. The quantitative relationship between 
road traﬃ  c noise and hypertension: a meta-analysis. J Hypertens 
2012; 30: 1075–86.
60 Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. 
Contributions of risk factors and medical care to cardiovascular 
mortality trends. Nat Rev Cardiol 2015; 12: 508–30.
61 Sakata K, Labarthe DR. Changes in cardiovascular disease risk 
factors in three Japanese national surveys 1971–1990. J Epidemiol 
1996; 6: 93–107.
62 Bernstein AM, Willett WC. Trends in 24-h urinary sodium excretion 
in the United States, 1957–2003: a systematic review. Am J Clin Nutr 
2010; 92: 1172–80.
63 Schiﬀ rin EL, Campbell NR, Feldman RD, et al. Hypertension in 
Canada: past, present, and future. Ann Glob Health 2016; 
82: 288–99.
64 Walker RL, Chen G, Campbell NR, et al. Canadian provincial trends 
in antihypertensive drug prescriptions between 1996 and 2006. 
Can J Cardiol 2011; 27: 461–67.
65 He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in 
England from 2003 to 2011: its relationship to blood pressure, 
stroke and ischaemic heart disease mortality. BMJ Open 2014; 
4: e004549.
66 Du S, Batis C, Wang H, Zhang B, Zhang J, Popkin BM. 
Understanding the patterns and trends of sodium intake, 
potassium intake, and sodium to potassium ratio and their eﬀ ect on 
hypertension in China. Am J Clin Nutr 2014; 99: 334–43.
67 Banegas JR, Navarro-Vidal B, Ruilope LM, et al. Trends in 
hypertension control among the older population of Spain from 
2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug 
treatment. Circ Cardiovasc Qual Outcomes 2015; 8: 67–76.
68 Blix HS, Landmark K, Selmer R, Reikvam A. Patterns in the 
prescription of antihypertensive drugs in Norway, 1975–2010. 
Tidsskr Nor Laegeforen 2012; 132: 1224–28 (in Norwegian).
69 Andersen UO, Jensen GB. Trends and determinant factors for 
population blood pressure with 25 years of follow-up: results from 
the Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 
2010; 17: 655–59.
70 Laatikainen T, Nissinen A, Kastarinen M, Jula A, Tuomilehto J. 
Blood pressure, sodium intake, and hypertension control: lessons 
from the North Karelia Project. Glob Heart 2016; 11: 191–99.
71 NCD Risk Factor Collaboration. Trends in adult body-mass index in 
200 countries from 1975 to 2014: a pooled analysis of 
1698 population-based measurement studies with 
19·2 million participants. Lancet 2016; 387: 1377–96.
72 Micha R, Khatibzadeh S, Shi P, et al. Global, regional and national 
consumption of major food groups in 1990 and 2010: a systematic 
analysis including 266 country-speciﬁ c nutrition surveys worldwide. 
BMJ Open 2015; 5: e008705.
73 Powles J, Fahimi S, Micha R, et al. Global, regional and national 
sodium intakes in 1990 and 2010: a systematic analysis of 24 h 
urinary sodium excretion and dietary surveys worldwide. BMJ Open 
2013; 3: e003733.
74 NCD Risk Factor Collaboration. A century of trends in adult human 
height. eLife 2016; 5: e13410.
75 Lee AC, Katz J, Blencowe H, et al. National and regional estimates 
of term and preterm babies born small for gestational age in 
138 low-income and middle-income countries in 2010. 
Lancet Glob Health 2013; 1: e26–36.
76 Stevens GA, Finucane MM, Paciorek CJ, et al. Trends in mild, 
moderate, and severe stunting and underweight, and progress 
towards MDG 1 in 141 developing countries: a systematic analysis of 
population representative data. Lancet 2012; 380: 824–34.
77 Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, 
treatment, and control of hypertension in rural and urban 
communities in high-, middle-, and low-income countries. JAMA 
2013; 310: 959–68.
78 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse 
strategy to address the global burden of raised blood pressure on 
current and future generations: the Lancet Commission on 
hypertension. Lancet 2016; published online Sept 23. http://dx.doi.
org/10.1016/S0140-6736(16)31134-5.
